Attention Deficit-Hyperactivity Disorder

Psychiatric MONDO:0007743 Pathograph 12 Show in embeddings browser Neurodevelopmental Disorder Mental Health Disorder

Attention deficit-hyperactivity disorder is a neurodevelopmental disorder characterized by developmentally inappropriate inattention and/or hyperactivity-impulsivity that interferes with functioning across settings.

Ask OpenScientist

Ask a research question about Attention Deficit-Hyperactivity Disorder. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

4
Pathophys.
3
Phenotypes
2
Hypotheses
3
Gaps
12
Pathograph
5
Medical Actions
3
Subtypes
6
Differentials
2
Datasets
2
Trials
12
References
2
Deep Research
◆

Subtypes

3
Combined presentation
DSM-5 presentation in which both inattentive and hyperactive-impulsive symptom domains meet threshold. Presentation labels describe the current symptom pattern and can change over time.
Show evidence (1 reference)
PMID:31570648 SUPPORT Human Clinical
"attention-deficit/hyperactivity disorder combined presentation (ADHD/C)"
The pediatric guideline reproduces the DSM-5 combined-presentation category; it does not imply a biologically discrete subtype.
Predominantly inattentive presentation
DSM-5 presentation in which inattentive symptoms meet threshold without the hyperactive-impulsive domain meeting threshold.
Show evidence (1 reference)
PMID:31570648 SUPPORT Human Clinical
"attention-deficit/hyperactivity disorder primarily of the inattentive presentation (ADHD/I) (314.00 [F90.0]);"
The pediatric guideline reproduces the DSM-5 predominantly inattentive presentation.
Predominantly hyperactive-impulsive presentation
DSM-5 presentation in which hyperactive-impulsive symptoms meet threshold without the inattentive domain meeting threshold.
Show evidence (1 reference)
PMID:31570648 SUPPORT Human Clinical
"attention-deficit/hyperactivity disorder primarily of the hyperactive-impulsive presentation (ADHD/HI) (314.01 [F90.1]);"
The pediatric guideline reproduces the DSM-5 predominantly hyperactive-impulsive presentation.
◈

Mechanistic Hypotheses

2
Genetically distinct sustained-attention and executive-function pathways
distinct_genetic_sa_ef EMERGING
Evidence balance 2 support
Genomic Structural Equation Modeling identified two partially distinct latent genetic factors: one influencing sustained attention (SA: vigilance, lapse recovery cost, lapse propensity) and one influencing executive function (EF: processing speed, response selection, working memory). Both factors show unique genetic correlations with ADHD liability and other psychiatric outcomes, suggesting that ADHD genetic heterogeneity may partly reflect differential loading on SA versus EF genetic architectures. This is an emerging hypothesis pending replication in more diverse populations.
Pathograph links
Executive attention and inhibitory-control variability -> Short Attention Span INDIRECT UNKNOWN INTERMEDIATES Executive-attention variability can contribute to inattention, but the cognitive route differs among individuals.
Executive attention and inhibitory-control variability -> Hyperactivity INDIRECT UNKNOWN INTERMEDIATES Inhibitory-control variability may contribute to hyperactive behavior, but this route is not universal.
Executive attention and inhibitory-control variability -> Impulsivity INDIRECT UNKNOWN INTERMEDIATES Inhibitory-control variability may contribute to impulsive behavior, but this route is not universal.
Show evidence (2 references)
PMID:42414552 SUPPORT Human Clinical
"We identified two distinct latent genetic factors: one influencing EF and one influencing SA. Both the EF and SA factors were genetically correlated with cognitive and clinical phenotypes, with each latent factor uniquely linked to liability for psychiatric disorders, including..."
The study is the first multivariate GWAS characterization of SA and EF genetic covariance (n>20,000, enriched for MDD/bipolar), showing that genetic influences on sustained attention are generally distinct from those influencing executive function, with both contributing uniquely to ADHD genetic risk.
PMID:42414552 SUPPORT Human Clinical
"They suggest that genetic influences on sustained attention are generally distinct from those that influence executive function. The EF and SA factors show distinct patterns of genetic overlap with multiple cognitive and psychiatric outcomes, underscoring the need for more granular cognitive..."
The paper directly supports the hypothesis of genetically distinct SA and EF pathways and their differential psychiatric correlations.
Genetically predicted brain expression, splicing, and methylation pathways
predicted_brain_multiomics_regulation EMERGING
Evidence balance 3 support
Mendelian-randomization and mediation analyses prioritize brain-tissue expression, alternative-splicing, and DNA-methylation signals. These are statistical predictions intended to guide experimental work, not validated universal mechanisms, causal genes, or clinical biomarkers.
Show evidence (3 references)
DOI:10.1093/bib/bbae502 SUPPORT Computational
"Finally, we also prioritized the expression of 866 genes showing significant causal effects, including COMMD5, ENSG00000271904, HYAL3, etc., within at least one brain tissue."
The analysis prioritizes statistically predicted expression effects; the hypothesis label and status prevent promotion to established causal genes.
DOI:10.1093/bib/bbae502 SUPPORT Computational
"We prioritized 966 unique genes that have statistically significant causal AS events, within at least one of the 14 different brain tissues."
The study reports predicted alternative-splicing signals across brain tissues, retained here as an emerging hypothesis.
DOI:10.1093/bib/bbae502 SUPPORT Computational
"Furthermore, through mediation analysis, 106 regulatory pathways were inferred where DNAm influences ADHD through gene expression or AS processes."
The source itself describes the methylation pathways as inferred, so they are not placed in the canonical causal graph.
?

Discussions and Knowledge Gaps

3
Should ADHD be represented as a Mendelian disorder with a causal gene list?
INTERPRETATION RESOLVED interpretation_polygenic_not_single_gene
Attached to
pathophysiology#Polygenic neurodevelopmental liability diagnosis#No standalone objective diagnostic test
Large association and family-trio studies support inherited polygenic susceptibility. Associated loci and predicted molecular targets are not deterministic causal genes and do not justify disease-level gene records or diagnostic genetic testing.
Show evidence (1 reference)
PMID:30478444 SUPPORT Human Clinical
"Common genetic variants contribute substantially to ADHD susceptibility, but no variants have been robustly associated with ADHD."
The GWAS frames ADHD in terms of distributed susceptibility rather than a single causal gene.
Should group-level imaging or multi-omics findings be used as ADHD diagnostic biomarkers?
INTERPRETATION RESOLVED interpretation_group_findings_not_biomarkers
Attached to
pathophysiology#Distributed neural-network differences mechanistic_hypotheses#predicted_brain_multiomics_regulation diagnosis#No standalone objective diagnostic test
Imaging effects are heterogeneous and method-sensitive, while multi-omics results are statistical predictions. Neither evidence stream establishes a sufficiently validated individual diagnostic test.
Show evidence (2 references)
PMID:28634439 SUPPORT Human Clinical
"The standardized effect size was rather small. These findings suggested a high heterogeneity of spontaneous brain activity in ADHD."
Small, inconsistent cohort effects argue against an individual functional imaging biomarker.
DOI:10.1093/bib/bbae502 SUPPORT Computational
"Our research findings provide guidance for future experimental studies on the molecular mechanisms of ADHD development"
The authors position their results as guidance for future experiments, consistent with hypothesis rather than biomarker status.
Which interventions produce durable improvements in adult functioning and quality of life, and for whom?
KNOWLEDGE GAP OPEN gap_long_term_and_adult_intervention_outcomes
Attached to
treatments#Stimulant pharmacotherapy treatments#Atomoxetine pharmacotherapy
Short-term symptom evidence is stronger than evidence for durable adult functional benefit, and nonpharmacologic adult results vary by rater.
Show evidence (1 reference)
PMID:39701638 SUPPORT Human Clinical
"Medications for ADHD were not efficacious on additional relevant outcomes, such as quality of life, and evidence in the longer term is underinvestigated."
The adult network meta-analysis directly identifies the long-term and functional-outcome evidence gap.
⚙

Pathophysiology

4
Polygenic neurodevelopmental liability
ADHD susceptibility is distributed across many common variants rather than explained by one Mendelian gene. Family-trio evidence supports transmission of polygenic liability, but this upstream risk does not specify one molecular pathway or predict an individual diagnosis.
Downstream
Distributed neural-network differences Polygenic liability is associated with neurodevelopmental differences, but the intervening molecular, cellular, and developmental routes remain heterogeneous and incompletely resolved.
Show evidence (3 references)
PMID:30478444 SUPPORT Human Clinical
"Common genetic variants contribute substantially to ADHD susceptibility, but no variants have been robustly associated with ADHD."
The large case-control GWAS establishes common-variant susceptibility and explains why a single causal-gene model is inappropriate.
PMID:30478444 SUPPORT Human Clinical
"identifies variants surpassing genome-wide significance in 12 independent loci, finding important new information about the underlying biology of ADHD."
Genome-wide significant loci support a polygenic architecture without elevating any one associated locus to deterministic causation.
DOI:10.1038/s41380-022-01863-6 SUPPORT Human Clinical
"Our findings indicate that the intergenerational transmission of risk for ADHD traits is largely explained by the transmission of genetic variants from parents to offspring rather than by genetic nurture."
The within-family trio analysis supports inherited polygenic liability for ADHD traits while not establishing a deterministic inheritance pattern.
Distributed neural-network differences
Group-level imaging studies report heterogeneous differences across distributed white-matter and functional networks. Findings are not present in every person, are sensitive to cohort and method, and are not diagnostic biomarkers.
brain UBERON:0000955 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in brain (UBERON:0000955). UBERON:0000955 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Executive attention and inhibitory-control variability Distributed network differences may contribute to attention and inhibitory-control variation, but imaging associations do not establish a universal individual-level causal chain.
Show evidence (2 references)
DOI:10.1038/s41380-023-02173-1 SUPPORT Human Clinical
"About 68% of studies were of low quality, mainly due to acquisitions with non-isotropic voxels or lack of motion correction; and the sensitivity analysis in high-quality datasets yielded no significant results."
The sensitivity result requires a provisional, non-diagnostic interpretation of group-level white-matter findings.
PMID:28634439 SUPPORT Human Clinical
"These findings suggested a high heterogeneity of spontaneous brain activity in ADHD."
Cross-cohort inconsistency directly supports heterogeneity rather than one universal functional-imaging signature.
Prefrontal catecholamine neuromodulation
Norepinephrine and dopamine modulate prefrontal cortical function, and established ADHD medications act on this system. This treatment-responsive control system is retained as a provisional disease mechanism; medication efficacy does not prove a universal baseline catecholamine deficiency.
dopaminergic neuron CL:0000700 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves dopaminergic neuron (CL:0000700). CL:0000700 is a cell type from the Cell Ontology. noradrenergic neuron CL:0008025 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves noradrenergic neuron (CL:0008025). CL:0008025 is a cell type from the Cell Ontology.
modulation of chemical synaptic transmission GO:0050804 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal modulation of chemical synaptic transmission (GO:0050804). GO:0050804 is a biological process from the Gene Ontology. ⚠ ABNORMAL
prefrontal cortex UBERON:0000451 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in prefrontal cortex (UBERON:0000451). UBERON:0000451 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Executive attention and inhibitory-control variability Catecholamine-dependent prefrontal regulation may influence attention and inhibitory control, but this is not asserted as the sole or universal route to ADHD symptoms.
Show evidence (2 references)
PMID:20596295 SUPPORT Human Clinical
"The PFC requires optimal levels of norepinephrine (NE) and dopamine (DA) for proper functioning."
The review establishes catecholamine dependence of prefrontal function but does not establish uniformly reduced transmitter release in ADHD.
PMID:20596295 SUPPORT Human Clinical
"Effective pharmacologic treatments for ADHD all enhance catecholamine signaling in the PFC and strengthen its regulation of attention and behavior."
Treatment pharmacology supports this system as clinically relevant, while response to treatment alone is not proof of the untreated disease state.
Executive attention and inhibitory-control variability
Difficulties with sustained attention, response inhibition, organization, or working memory occur in many people with ADHD, but no single executive deficit is required or specific enough to define the disorder.
Genetically distinct sustained-attention and executive-function pathways
cognition GO:0050890 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal cognition (GO:0050890). GO:0050890 is a biological process from the Gene Ontology. ⚠ ABNORMAL
prefrontal cortex UBERON:0000451 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in prefrontal cortex (UBERON:0000451). UBERON:0000451 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Short Attention Span Executive-attention variability can contribute to inattention, but the cognitive route differs among individuals. Genetically distinct sustained-attention and executive-function pathways
Hyperactivity Inhibitory-control variability may contribute to hyperactive behavior, but this route is not universal. Genetically distinct sustained-attention and executive-function pathways
Impulsivity Inhibitory-control variability may contribute to impulsive behavior, but this route is not universal. Genetically distinct sustained-attention and executive-function pathways
Show evidence (2 references)
PMID:20596295 SUPPORT Human Clinical
"The PFC is essential for the so-called executive functions, allowing us to organize and plan for the future and to inhibit responses to distractions in order to achieve a goal."
The review supplies a plausible cognitive-control framework without showing that one executive deficit is necessary in all ADHD.
DOI:10.1002/wps.21374 SUPPORT Human Clinical
"Key uncertainties and controversies on adult ADHD include: a) the possibility of late‐onset ADHD; b) the significance of emotional dysregulation as a core symptom; c) the definition and characterization of functional impairment; d) the persistence of comorbid psychiatric and somatic conditions..."
The current adult review explicitly identifies the definitional relevance of executive dysfunction as unresolved.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Attention Deficit-Hyperactivity Disorder Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

3
Nervous System 1
Hyperactivity HP:0000752 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyperactivity (HP:0000752). HP:0000752 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31570648 SUPPORT Human Clinical
"The pediatrician or other PCC should initiate an evaluation for ADHD for any child or adolescent age 4 years to the 18th birthday who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity"
The guideline identifies hyperactivity as a core symptom domain while the presentation structure prevents treating it as universal.
Other 2
Short Attention Span HP:0000736 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Short attention span (HP:0000736). HP:0000736 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31570648 SUPPORT Human Clinical
"The pediatrician or other PCC should initiate an evaluation for ADHD for any child or adolescent age 4 years to the 18th birthday who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity"
The guideline identifies inattention as a core symptom domain prompting ADHD evaluation; impairment and multi-setting criteria are addressed in the diagnosis section.
Impulsivity HP:0100710 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Impulsivity (HP:0100710). HP:0100710 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31570648 SUPPORT Human Clinical
"The pediatrician or other PCC should initiate an evaluation for ADHD for any child or adolescent age 4 years to the 18th birthday who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity"
The guideline explicitly identifies impulsivity as a core symptom domain.
💊

Medical Actions

5
Behavioral parent training and classroom intervention
Category: Therapeutic Action: behavioral counselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is behavioral counseling (NCIT:C181743). NCIT:C181743 is a clinical intervention from the NCI Thesaurus. Ontology label: Behavioral Counseling NCIT:C181743
Evidence-based parent training in behavior management and behavioral classroom intervention are first-line for preschool-aged children and remain components of multimodal care for school-age children. Availability, developmental level, family priorities, and functional goals shape delivery.
Target Phenotypes: Short attention span HP:0000736 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Short attention span (HP:0000736). HP:0000736 is a phenotype from the Human Phenotype Ontology. Hyperactivity HP:0000752 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hyperactivity (HP:0000752). HP:0000752 is a phenotype from the Human Phenotype Ontology. Impulsivity HP:0100710 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Impulsivity (HP:0100710). HP:0100710 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:31570648 SUPPORT Human Clinical
"For preschool-aged children (age 4 years to the sixth birthday) with ADHD, the PCC should prescribe evidence-based behavioral PTBM and/or behavioral classroom interventions as the first line of treatment, if available"
The guideline makes these behavioral interventions first-line in the preschool age group.
PMID:31570648 SUPPORT Human Clinical
"For elementary and middle school–aged children (age 6 years to the 12th birthday) with ADHD, the PCC should prescribe US Food and Drug Administration (FDA)–approved medications for ADHD, along with PTBM and/or behavioral classroom intervention (preferably both PTBM and behavioral classroom..."
The school-age recommendation supports behavioral care as part of combined management rather than as a universal stand-alone substitute.
Educational interventions and individualized school supports
Category: Therapeutic Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
School-environment changes, instructional placement, behavioral supports, and an individualized education or accommodation plan address functional impairment. Applicable supports depend on local law and the learner's assessed needs.
Target Phenotypes: Short attention span HP:0000736 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Short attention span (HP:0000736). HP:0000736 is a phenotype from the Human Phenotype Ontology. Hyperactivity HP:0000752 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hyperactivity (HP:0000752). HP:0000752 is a phenotype from the Human Phenotype Ontology. Impulsivity HP:0100710 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Impulsivity (HP:0100710). HP:0100710 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31570648 SUPPORT Human Clinical
"Educational interventions and individualized instructional supports, including school environment, class placement, instructional placement, and behavioral supports, are a necessary part of any treatment plan and often include an Individualized Education Program (IEP) or a rehabilitation plan (504 plan)"
The guideline directly supports individualized educational and school supports, with US plan names retained only as examples.
Stimulant pharmacotherapy
Category: Therapeutic Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: methylphenidate CHEBI:6887 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses methylphenidate (CHEBI:6887). CHEBI:6887 is a therapeutic agent from Chemical Entities of Biological Interest. amphetamine CHEBI:2679 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses amphetamine (CHEBI:2679). CHEBI:2679 is a therapeutic agent from Chemical Entities of Biological Interest.
Methylphenidate- or amphetamine-class medication can reduce core ADHD symptoms. Pediatric use is age- and severity-dependent; preschool use has additional restrictions. Adult evidence supports short-term symptom benefit, while long-term outcomes require further study. Dose and adverse effects require individualized monitoring.
Mechanism Target:
Prefrontal catecholamine neuromodulation — Stimulants inhibit dopamine and norepinephrine transporters, altering catecholamine availability; this pharmacology does not prove a universal untreated catecholamine deficit.
Show evidence (1 reference)
PMID:20596295 SUPPORT Human Clinical
"block both catecholamine transporters, the transporter for DA and that for NE."
The review supplies the transporter-level drug action used for the treatment-target link.
Target Phenotypes: Short attention span HP:0000736 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Short attention span (HP:0000736). HP:0000736 is a phenotype from the Human Phenotype Ontology. Hyperactivity HP:0000752 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hyperactivity (HP:0000752). HP:0000752 is a phenotype from the Human Phenotype Ontology. Impulsivity HP:0100710 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Impulsivity (HP:0100710). HP:0100710 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:31570648 SUPPORT Human Clinical
"The evidence is particularly strong for stimulant medications; it is sufficient, but not as strong, for atomoxetine, extended-release guanfacine, and extended-release clonidine, in that order"
The pediatric guideline establishes the relative evidence base for stimulant and selected nonstimulant medication.
PMID:39701638 SUPPORT Human Clinical
"Stimulants and atomoxetine were the only interventions with evidence of beneficial effects in terms of reducing ADHD core symptoms in the short term, supported by both self-reported and clinician-reported ratings."
The adult network meta-analysis supports short-term core-symptom benefit and prevents extrapolation to unstudied long-term outcomes.
PMID:31570648 SUPPORT Human Clinical
"The PCC should titrate doses of medication for ADHD to achieve maximum benefit with tolerable side effects"
The recommendation supports individualized titration and tolerability monitoring rather than a fixed regimen.
Atomoxetine pharmacotherapy
Category: Therapeutic Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: atomoxetine CHEBI:127342 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses atomoxetine (CHEBI:127342). CHEBI:127342 is a therapeutic agent from Chemical Entities of Biological Interest.
Atomoxetine is a nonstimulant norepinephrine-transporter inhibitor with evidence for pediatric and short-term adult core-symptom reduction. Choice depends on age, comorbidity, contraindications, prior response, preferences, and adverse-effect monitoring.
Mechanism Target:
Prefrontal catecholamine neuromodulation — Atomoxetine inhibits the norepinephrine transporter and thereby modulates prefrontal catecholamine signaling.
Show evidence (1 reference)
PMID:20596295 SUPPORT Human Clinical
"selectively blocks the NE transporter."
The review directly supports the norepinephrine-transporter target.
Target Phenotypes: Short attention span HP:0000736 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Short attention span (HP:0000736). HP:0000736 is a phenotype from the Human Phenotype Ontology. Hyperactivity HP:0000752 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hyperactivity (HP:0000752). HP:0000752 is a phenotype from the Human Phenotype Ontology. Impulsivity HP:0100710 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Impulsivity (HP:0100710). HP:0100710 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:31570648 SUPPORT Human Clinical
"The evidence is particularly strong for stimulant medications; it is sufficient, but not as strong, for atomoxetine, extended-release guanfacine, and extended-release clonidine, in that order"
The guideline supports atomoxetine while preserving the weaker evidence ranking relative to stimulants in pediatric care.
PMID:39701638 SUPPORT Human Clinical
"However, atomoxetine was less acceptable than placebo. Medications for ADHD were not efficacious on additional relevant outcomes, such as quality of life, and evidence in the longer term is underinvestigated."
This snippet is a caveat on acceptability and long-term evidence, not an efficacy statement; it qualifies rather than supports the atomoxetine treatment claim.
Extended-release guanfacine or clonidine pharmacotherapy
Category: Therapeutic Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: guanfacine CHEBI:5558 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses guanfacine (CHEBI:5558). CHEBI:5558 is a therapeutic agent from Chemical Entities of Biological Interest. clonidine NCIT:C380 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses clonidine (NCIT:C380). NCIT:C380 is a therapeutic agent from the NCI Thesaurus.
Extended-release alpha-2 adrenergic agonists are pediatric nonstimulant options with a smaller evidence base than stimulants. Sedation, hypotension, cardiovascular effects, age, formulation, and comorbidity require individualized assessment; this record does not generalize pediatric evidence to adults.
Mechanism Target:
Prefrontal catecholamine neuromodulation — Guanfacine acts at postsynaptic alpha-2A receptors in prefrontal cortex; the shared target node represents drug action, not a universal receptor defect in ADHD.
Show evidence (1 reference)
PMID:20596295 SUPPORT Human Clinical
"Guanfacine acts directly at postsynaptic, alpha-2A receptors in the PFC, where it mimics the beneficial effects of NE and strengthens PFC regulation of attention and behavior."
The review provides receptor- and location-specific support for the guanfacine treatment-target link.
Target Phenotypes: Short attention span HP:0000736 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Short attention span (HP:0000736). HP:0000736 is a phenotype from the Human Phenotype Ontology. Hyperactivity HP:0000752 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hyperactivity (HP:0000752). HP:0000752 is a phenotype from the Human Phenotype Ontology. Impulsivity HP:0100710 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Impulsivity (HP:0100710). HP:0100710 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31570648 SUPPORT Human Clinical
"The evidence is particularly strong for stimulant medications; it is sufficient, but not as strong, for atomoxetine, extended-release guanfacine, and extended-release clonidine, in that order"
The guideline supports both extended-release alpha-2 agonists in school-age pediatric care while ranking their evidence below stimulants.
🔬

Diagnosis

3
DSM-5 clinical assessment across settings (Diagnosis requires developmentally inappropriate symptoms and impairment, DSM-5 criteria, evidence across more than one major setting, collateral information, and exclusion of alternative explanations. A symptom report in one context alone is insufficient.)
clinical assessment NCIT:C124351 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:31570648 SUPPORT Human Clinical
"To make a diagnosis of ADHD, the PCC should determine that DSM-5 criteria have been met, including documentation of symptoms and impairment in more than 1 major setting (ie, social, academic, or occupational), with information obtained primarily from reports from parents or guardians, teachers,..."
This directly supports the pediatric multi-setting, multi-informant clinical diagnostic standard and alternative-cause exclusion.
Structured symptom ratings and developmental history (DSM-based rating scales organize reports from relevant observers but are interpreted within a clinical and developmental assessment. For adolescents and adults, childhood onset or manifestations must be established rather than inferred from current symptoms alone.)
clinical assessment NCIT:C124351 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:31570648 SUPPORT Human Clinical
"To make a diagnosis of ADHD in preschool-aged children, clinicians should conduct a clinical interview with parents, examine and observe the child, and obtain information from parents and teachers through DSM-based ADHD rating scales."
The guideline supports rating scales as structured inputs to, rather than substitutes for, a clinical assessment.
PMID:31570648 SUPPORT Human Clinical
"to meet DSM-5 criteria for ADHD, adolescents must have some reported or documented manifestations of inattention or hyperactivity/impulsivity before age 12."
This anchors adolescent diagnosis in developmental history; adult assessment likewise requires careful evaluation of childhood onset.
No standalone objective diagnostic test (Neuropsychological testing may clarify strengths and weaknesses, but it does not usually improve diagnostic accuracy. Neuroimaging, molecular findings, polygenic scores, and medication response are not standalone ADHD diagnostic tests.)
clinical assessment NCIT:C124351 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:31570648 SUPPORT Human Clinical
"The use of neuropsychological testing has not been found to improve diagnostic accuracy in most cases, although it may have benefit in clarifying the child or adolescent’s learning strengths and weaknesses."
The guideline explicitly distinguishes diagnostic accuracy from the narrower value of testing for a learning profile.
DOI:10.1002/wps.21374 SUPPORT Human Clinical
"Key uncertainties and controversies on adult ADHD include: a) the possibility of late‐onset ADHD; b) the significance of emotional dysregulation as a core symptom; c) the definition and characterization of functional impairment; d) the persistence of comorbid psychiatric and somatic conditions..."
The adult review identifies objective measures as an unresolved area and does not endorse a standalone biomarker.
📈

Progression

3
Childhood onset and school-age recognition
Age: Childhood
ADHD symptoms arise in childhood. Recognition often occurs when academic, behavioral, or social demands make impairment across settings apparent; diagnostic criteria require developmental context rather than isolated behavior in one setting.
Show evidence (1 reference)
PMID:31570648 SUPPORT Human Clinical
"Symptoms of ADHD occur in childhood, and most children with ADHD will continue to have symptoms and impairment through adolescence and into adulthood."
The guideline supports childhood onset and persistence while avoiding a claim that every child has the same course.
Adolescent symptom-pattern change
Age: Adolescence
Overt hyperactivity and impulsivity often decline with age, whereas inattentive symptoms are more likely to persist; individual trajectories vary and functional impairment may continue.
Show evidence (1 reference)
PMID:31570648 SUPPORT Human Clinical
"As individuals with ADHD enter adolescence, their overt hyperactive and impulsive symptoms tend to decline, whereas their inattentive symptoms tend to persist."
This supports a common age-related pattern without treating it as an obligatory trajectory.
Adult persistence or partial remission
Age: Adulthood
Childhood-onset ADHD may remain fully syndromal, persist with impairing symptoms below formal threshold, or remit. Adult assessment must establish developmental continuity while considering unresolved late-onset claims.
Show evidence (1 reference)
DOI:10.1002/wps.21374 SUPPORT Human Clinical
"Additionally, up to 70% of individuals with childhood‐onset ADHD continue to experience impairing symptoms as adults, even if they no longer meet the criteria for a formal diagnosis."
The review supports heterogeneous persistence, including subthreshold but impairing adult symptoms.
📊

Prevalence

2
Children worldwide
Point Prevalence 7200.0 per 100,000 >1 in 1,000
Pooled estimate reported by the AAP guideline. Estimates vary with age, sampling, diagnostic criteria, and ascertainment, so 7.2% should not be treated as a universal fixed rate.
Show evidence (1 reference)
PMID:31570648 SUPPORT Human Clinical
"Authors of a recent meta-analysis calculated a pooled worldwide ADHD prevalence of 7.2% among children"
The guideline reports the pooled worldwide pediatric estimate used for the normalized rate.
Adults worldwide
Point Prevalence 2500.0 per 100,000 >1 in 1,000
Approximate worldwide adult prevalence from a 2025 evidence review; case definition and ascertainment remain important sources of variation.
Show evidence (1 reference)
DOI:10.1002/wps.21374 SUPPORT Human Clinical
"Now it is well established that it can persist into adulthood, with an estimated worldwide prevalence of around 2.5%."
The review directly supplies the approximate adult worldwide prevalence.
⚖️

Clinical Burden

Variable
ADHD can impose persistent educational, occupational, interpersonal, safety, and mental-health burden, but severity, presentation, comorbidity, support, and course vary widely. No single low, moderate, or high category represents the full population.
Show evidence (3 references)
PMID:31570648 SUPPORT Human Clinical
"patients with ADHD, whether treated or not, are at increased risk for early death, suicide, and increased psychiatric comorbidity, particularly substance use disorders."
The guideline documents important long-term risks at the population level; these associations do not determine an individual's outcome.
PMID:31570648 SUPPORT Human Clinical
"They also have lower educational achievement than those without ADHD"
Population-level educational outcomes support clinically meaningful burden while the rationale preserves individual variability.
DOI:10.1002/wps.21374 SUPPORT Human Clinical
"Additionally, up to 70% of individuals with childhood‐onset ADHD continue to experience impairing symptoms as adults, even if they no longer meet the criteria for a formal diagnosis."
Persistence of impairing symptoms beyond formal diagnostic threshold supports longitudinal burden and variability.
🔀

Differential Diagnoses

6

Conditions with similar clinical presentations that must be differentiated from Attention Deficit-Hyperactivity Disorder:

Major depressive disorder MONDO:0002009
Overlapping Features Depression can cause concentration, motivation, sleep, and functional difficulties that mimic or coexist with ADHD. Mood course, developmental onset, and cross-setting persistence help determine attribution.
Show evidence (1 reference)
PMID:31570648 SUPPORT Human Clinical
"strongly consider whether a mimicking or comorbid condition, such as substance use, depression, and/or anxiety, is present."
The guideline explicitly identifies depression as a mimicking or comorbid condition during adolescent assessment.
Generalized anxiety disorder MONDO:0001942
Overlapping Features Anxiety-related worry, arousal, avoidance, and sleep disruption can impair concentration or coexist with ADHD. The temporal pattern and anxiety-linked context should be assessed.
Show evidence (1 reference)
PMID:31570648 SUPPORT Human Clinical
"strongly consider whether a mimicking or comorbid condition, such as substance use, depression, and/or anxiety, is present."
The guideline explicitly includes anxiety in the mimic/comorbidity assessment.
Specific learning disability Not Yet Curated MONDO:0016225
Overlapping Features A learning disorder can produce task-specific academic difficulty, avoidance, or apparent inattention and frequently coexists with ADHD. Assessment should distinguish a circumscribed learning profile from cross-setting ADHD symptoms.
Show evidence (1 reference)
PMID:31570648 SUPPORT Human Clinical
"In the evaluation of a child or adolescent for ADHD, the PCC should include a process to at least screen for comorbid conditions, including emotional or behavioral conditions (eg, anxiety, depression, oppositional defiant disorder, conduct disorders, substance use), developmental conditions (eg,..."
The guideline requires screening for learning disorders during ADHD evaluation.
Autism spectrum disorder MONDO:0005258
Overlapping Features Autism-related social-communication differences, restricted behavior, and executive or sensory difficulties may overlap with ADHD symptoms, and both diagnoses can coexist.
Show evidence (1 reference)
PMID:31570648 SUPPORT Human Clinical
"In the evaluation of a child or adolescent for ADHD, the PCC should include a process to at least screen for comorbid conditions, including emotional or behavioral conditions (eg, anxiety, depression, oppositional defiant disorder, conduct disorders, substance use), developmental conditions (eg,..."
The guideline explicitly includes autism spectrum disorders in the developmental comorbidity screen.
Obstructive sleep apnea syndrome MONDO:0007147
Overlapping Features Sleep-disordered breathing can produce daytime inattention, behavioral dysregulation, or sleepiness. Sleep history and physical evaluation are important when symptoms or risk factors suggest it.
Show evidence (1 reference)
PMID:31570648 SUPPORT Human Clinical
"In the evaluation of a child or adolescent for ADHD, the PCC should include a process to at least screen for comorbid conditions, including emotional or behavioral conditions (eg, anxiety, depression, oppositional defiant disorder, conduct disorders, substance use), developmental conditions (eg,..."
Sleep apnea is explicitly included in the physical-condition screen.
📊

Related Datasets

2
Brain tissue multi-omics Mendelian-randomization analysis for ADHD DOI:10.1093/bib/bbae502
Integrative multi-omics dataset combining ADHD GWAS summary data with expression, alternative splicing, and DNA methylation quantitative trait loci across 14 brain tissues. The Mendelian-randomization and mediation results are predicted or inferred and require experimental validation.
Homo sapiens
Conditions: attention deficit-hyperactivity disorder brain gene expression alternative splicing DNA methylation
Findings
Mediation analysis inferred DNA-methylation pathways through gene expression or alternative splicing.
Show evidence (1 reference)
DOI:10.1093/bib/bbae502 SUPPORT Computational
"Furthermore, through mediation analysis, 106 regulatory pathways were inferred where DNAm influences ADHD through gene expression or AS processes."
Captures the analysis as an inference rather than an established individual-level disease mechanism.
DOI:10.1093/bib/bbae502
Show evidence (1 reference)
DOI:10.1093/bib/bbae502 SUPPORT Computational
"In this paper, a multi-omics study was conducted to investigate the causal effects of the transcription and the DNAm on ADHD, by integrating ADHD genome-wide association data with quantitative trait loci data of gene expression, AS, and DNAm across 14 different brain tissues."
The publication describes a reusable integrative brain multi-omics analysis dataset for ADHD molecular mechanisms.
ADHD-200 Global Competition: diagnosing ADHD using personal characteristic data can outperform resting state fMRI measurements. PMID:23060754
Multi-site ADHD-control neuroimaging dataset with resting-state fMRI, structural MRI, demographic, IQ, and diagnostic data used in the ADHD-200 Global Competition.
Homo sapiens n=973
Conditions: attention deficit-hyperactivity disorder healthy control
Findings
ADHD-200 analyses show heterogeneity across cohorts in spontaneous brain activity.
Show evidence (1 reference)
PMID:28634439 SUPPORT Human Clinical
"These findings suggested a high heterogeneity of spontaneous brain activity in ADHD."
Independent ADHD-200 analysis cautions that multi-site pooled neuroimaging findings vary across cohorts.
PMID:23060754
Show evidence (1 reference)
PMID:23060754 SUPPORT Human Clinical
"The ADHD-200 dataset is the first publicly-available dataset with fMRI scans from on-the-order-of one thousand participants, including both psychiatric patients and healthy controls."
The paper documents ADHD-200 as a large public neuroimaging dataset for ADHD and control participants.
🔬

Clinical Trials

2
NCT02155608 NOT_APPLICABLE COMPLETED
Developmental pilot study of external trigeminal nerve stimulation as a potential nonmedication intervention for ADHD symptoms and executive function measures.
Target Phenotypes: Short attention span HP:0000736 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Short attention span (HP:0000736). HP:0000736 is a phenotype from the Human Phenotype Ontology. Hyperactivity HP:0000752 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Hyperactivity (HP:0000752). HP:0000752 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT02155608 SUPPORT
"The purpose of this study is to develop external Trigeminal Nerve Stimulation (eTNS) as a potential nonmedication treatment for attention-deficit/hyperactivity disorder (ADHD)."
ClinicalTrials.gov record documents a pilot neuromodulation trial targeting ADHD symptoms.
NCT05374187 NOT_APPLICABLE COMPLETED
Multisite randomized clinical trial of external trigeminal nerve stimulation for ADHD in children aged 7-12 years. ClinicalTrials.gov listed the study as completed when the registry was rechecked on 2026-07-20; results had not yet been posted in the registry response.
Target Phenotypes: Short attention span HP:0000736 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Short attention span (HP:0000736). HP:0000736 is a phenotype from the Human Phenotype Ontology. Hyperactivity HP:0000752 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Hyperactivity (HP:0000752). HP:0000752 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT05374187 SUPPORT
"This study is a large multisite randomized clinical trial to asses the efficacy of external trigeminal nerve stimulation (TNS), a novel, minimal risk, non-invasive neuromodulation treatment, for ADHD in children ages 7-12 years old (N=180)."
ClinicalTrials.gov record documents an RCT of TNS for pediatric ADHD.
{ }

Source YAML

click to show 
name: Attention Deficit-Hyperactivity Disorder
creation_date: "2026-04-24T20:56:38Z"
category: Psychiatric
description: >-
  Attention deficit-hyperactivity disorder is a neurodevelopmental disorder
  characterized by developmentally inappropriate inattention and/or
  hyperactivity-impulsivity that interferes with functioning across settings.
synonyms:
- ADHD
- attention deficit hyperactivity disorder
- attention deficit/hyperactivity disorder
disease_term:
  preferred_term: attention deficit-hyperactivity disorder
  term:
    id: MONDO:0007743
    label: attention deficit-hyperactivity disorder
parents:
- Neurodevelopmental Disorder
- Mental Health Disorder
tracked_issues:
- url: https://github.com/monarch-initiative/dismech/issues/1448
  title: Representing circuit-level and psychiatric disorders in DisMech (example ADHD)
  tracked_issue_role: curation_followup
  tracked_issue_status: CLOSED
  notes: >-
    ADHD is used here as a prototype for representing circuit-level
    neurodevelopmental and psychiatric mechanisms with the current DisMech
    pathophysiology model. The issue is resolved: this entry shipped as the
    prototype, and the general guidance it produced is recorded in
    docs/psychiatric-curation-sop.md (commit 70be96dde9). The conclusion was
    that no schema extension is required — circuit-level mechanisms are
    expressible with multi-region UBERON locations, CL cell types, and GO
    processes on ordinary pathophysiology nodes.
has_subtypes:
- name: Combined
  display_name: Combined presentation
  description: >-
    DSM-5 presentation in which both inattentive and hyperactive-impulsive
    symptom domains meet threshold. Presentation labels describe the current
    symptom pattern and can change over time.
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "attention-deficit/hyperactivity disorder combined presentation (ADHD/C)"
    explanation: >-
      The pediatric guideline reproduces the DSM-5 combined-presentation
      category; it does not imply a biologically discrete subtype.
- name: Inattentive
  display_name: Predominantly inattentive presentation
  description: >-
    DSM-5 presentation in which inattentive symptoms meet threshold without the
    hyperactive-impulsive domain meeting threshold.
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "attention-deficit/hyperactivity disorder primarily of the inattentive presentation (ADHD/I) (314.00 [F90.0]);"
    explanation: >-
      The pediatric guideline reproduces the DSM-5 predominantly inattentive
      presentation.
- name: Hyperactive-Impulsive
  display_name: Predominantly hyperactive-impulsive presentation
  description: >-
    DSM-5 presentation in which hyperactive-impulsive symptoms meet threshold
    without the inattentive domain meeting threshold.
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "attention-deficit/hyperactivity disorder primarily of the hyperactive-impulsive presentation (ADHD/HI) (314.01 [F90.1]);"
    explanation: >-
      The pediatric guideline reproduces the DSM-5 predominantly
      hyperactive-impulsive presentation.
prevalence:
- population: Children worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 7200.0
  notes: >-
    Pooled estimate reported by the AAP guideline. Estimates vary with age,
    sampling, diagnostic criteria, and ascertainment, so 7.2% should not be
    treated as a universal fixed rate.
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Authors of a recent meta-analysis calculated a pooled worldwide ADHD prevalence of 7.2% among children"
    explanation: >-
      The guideline reports the pooled worldwide pediatric estimate used for
      the normalized rate.
- population: Adults worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 2500.0
  notes: >-
    Approximate worldwide adult prevalence from a 2025 evidence review; case
    definition and ascertainment remain important sources of variation.
  evidence:
  - reference: DOI:10.1002/wps.21374
    reference_title: "Attention‐deficit/hyperactivity disorder (<scp>ADHD</scp>) in adults: evidence base, uncertainties and controversies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Now it is well established that it can persist into adulthood, with an estimated worldwide prevalence of around 2.5%."
    explanation: >-
      The review directly supplies the approximate adult worldwide prevalence.
progression:
- phase: Childhood onset and school-age recognition
  age_range: Childhood
  notes: >-
    ADHD symptoms arise in childhood. Recognition often occurs when academic,
    behavioral, or social demands make impairment across settings apparent;
    diagnostic criteria require developmental context rather than isolated
    behavior in one setting.
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Symptoms of ADHD occur in childhood, and most children with ADHD will
      continue to have symptoms and impairment through adolescence and into
      adulthood.
    explanation: >-
      The guideline supports childhood onset and persistence while avoiding a
      claim that every child has the same course.
- phase: Adolescent symptom-pattern change
  age_range: Adolescence
  notes: >-
    Overt hyperactivity and impulsivity often decline with age, whereas
    inattentive symptoms are more likely to persist; individual trajectories
    vary and functional impairment may continue.
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      As individuals with ADHD enter adolescence, their overt hyperactive and
      impulsive symptoms tend to decline, whereas their inattentive symptoms
      tend to persist.
    explanation: >-
      This supports a common age-related pattern without treating it as an
      obligatory trajectory.
- phase: Adult persistence or partial remission
  age_range: Adulthood
  notes: >-
    Childhood-onset ADHD may remain fully syndromal, persist with impairing
    symptoms below formal threshold, or remit. Adult assessment must establish
    developmental continuity while considering unresolved late-onset claims.
  evidence:
  - reference: DOI:10.1002/wps.21374
    reference_title: "Attention‐deficit/hyperactivity disorder (<scp>ADHD</scp>) in adults: evidence base, uncertainties and controversies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additionally, up to 70% of individuals with childhood‐onset ADHD continue
      to experience impairing symptoms as adults, even if they no longer meet
      the criteria for a formal diagnosis.
    explanation: >-
      The review supports heterogeneous persistence, including subthreshold but
      impairing adult symptoms.
pathophysiology:
- name: Polygenic neurodevelopmental liability
  description: >-
    ADHD susceptibility is distributed across many common variants rather than
    explained by one Mendelian gene. Family-trio evidence supports transmission
    of polygenic liability, but this upstream risk does not specify one molecular
    pathway or predict an individual diagnosis.
  mechanism_confidence: ESTABLISHED
  evidence:
  - reference: PMID:30478444
    reference_title: Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Common genetic variants contribute substantially to ADHD susceptibility,
      but no variants have been robustly associated with ADHD.
    explanation: >-
      The large case-control GWAS establishes common-variant susceptibility and
      explains why a single causal-gene model is inappropriate.
  - reference: PMID:30478444
    reference_title: Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      identifies variants surpassing genome-wide significance in 12 independent
      loci, finding important new information about the underlying biology of
      ADHD.
    explanation: >-
      Genome-wide significant loci support a polygenic architecture without
      elevating any one associated locus to deterministic causation.
  - reference: DOI:10.1038/s41380-022-01863-6
    reference_title: Genetic nurture versus genetic transmission of risk for ADHD traits in the Norwegian Mother, Father and Child Cohort Study
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our findings indicate that the intergenerational transmission of risk for
      ADHD traits is largely explained by the transmission of genetic variants
      from parents to offspring rather than by genetic nurture.
    explanation: >-
      The within-family trio analysis supports inherited polygenic liability for
      ADHD traits while not establishing a deterministic inheritance pattern.
  downstream:
  - target: Distributed neural-network differences
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Polygenic liability is associated with neurodevelopmental differences,
      but the intervening molecular, cellular, and developmental routes remain
      heterogeneous and incompletely resolved.
    evidence:
    - reference: DOI:10.1038/s41380-023-02173-1
      reference_title: "White matter alterations in Attention-Deficit/Hyperactivity Disorder (ADHD): a systematic review of 129 diffusion imaging studies with meta-analysis"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Multiple genetic and environmental factors contribute to ADHD, but it is
        unclear how they interplay with brain development to produce symptoms
      explanation: >-
        The review supports a neurodevelopmental link while explicitly stating
        that the intervening causal pathway is unresolved.
- name: Distributed neural-network differences
  description: >-
    Group-level imaging studies report heterogeneous differences across
    distributed white-matter and functional networks. Findings are not present
    in every person, are sensitive to cohort and method, and are not diagnostic
    biomarkers.
  mechanism_confidence: PROVISIONAL
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: DOI:10.1038/s41380-023-02173-1
    reference_title: "White matter alterations in Attention-Deficit/Hyperactivity Disorder (ADHD): a systematic review of 129 diffusion imaging studies with meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      About 68% of studies were of low quality, mainly due to acquisitions with
      non-isotropic voxels or lack of motion correction; and the sensitivity
      analysis in high-quality datasets yielded no significant results.
    explanation: >-
      The sensitivity result requires a provisional, non-diagnostic
      interpretation of group-level white-matter findings.
  - reference: PMID:28634439
    reference_title: Inconsistency in Abnormal Brain Activity across Cohorts of ADHD-200 in Children with Attention Deficit Hyperactivity Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These findings suggested a high heterogeneity of spontaneous brain
      activity in ADHD.
    explanation: >-
      Cross-cohort inconsistency directly supports heterogeneity rather than one
      universal functional-imaging signature.
  downstream:
  - target: Executive attention and inhibitory-control variability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Distributed network differences may contribute to attention and
      inhibitory-control variation, but imaging associations do not establish a
      universal individual-level causal chain.
    evidence:
    - reference: DOI:10.1038/s41380-023-02173-1
      reference_title: "White matter alterations in Attention-Deficit/Hyperactivity Disorder (ADHD): a systematic review of 129 diffusion imaging studies with meta-analysis"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The systematic review highlighted white matter alterations (especially
        reduced FA) in projection, commissural and association pathways of
        individuals with ADHD, which were associated with symptom severity and
        cognitive deficits.
      explanation: >-
        The association supports a possible link to cognition, but it does not
        resolve directionality or demonstrate mediation in individuals.
- name: Prefrontal catecholamine neuromodulation
  description: >-
    Norepinephrine and dopamine modulate prefrontal cortical function, and
    established ADHD medications act on this system. This treatment-responsive
    control system is retained as a provisional disease mechanism; medication
    efficacy does not prove a universal baseline catecholamine deficiency.
  mechanism_confidence: PROVISIONAL
  cell_types:
  - preferred_term: dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  - preferred_term: noradrenergic neuron
    term:
      id: CL:0008025
      label: noradrenergic neuron
  biological_processes:
  - preferred_term: modulation of chemical synaptic transmission
    term:
      id: GO:0050804
      label: modulation of chemical synaptic transmission
    modifier: ABNORMAL
  locations:
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  evidence:
  - reference: PMID:20596295
    reference_title: "The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The PFC requires optimal levels of norepinephrine (NE) and dopamine (DA)
      for proper functioning.
    explanation: >-
      The review establishes catecholamine dependence of prefrontal function but
      does not establish uniformly reduced transmitter release in ADHD.
  - reference: PMID:20596295
    reference_title: "The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Effective pharmacologic treatments for ADHD all enhance catecholamine
      signaling in the PFC and strengthen its regulation of attention and
      behavior.
    explanation: >-
      Treatment pharmacology supports this system as clinically relevant, while
      response to treatment alone is not proof of the untreated disease state.
  downstream:
  - target: Executive attention and inhibitory-control variability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Catecholamine-dependent prefrontal regulation may influence attention and
      inhibitory control, but this is not asserted as the sole or universal
      route to ADHD symptoms.
    evidence:
    - reference: PMID:20596295
      reference_title: "The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Effective pharmacologic treatments for ADHD all enhance catecholamine
        signaling in the PFC and strengthen its regulation of attention and
        behavior.
      explanation: >-
        The review supports functional relevance of the system, while the edge
        remains indirect and explicitly non-universal.
- name: Executive attention and inhibitory-control variability
  description: >-
    Difficulties with sustained attention, response inhibition, organization,
    or working memory occur in many people with ADHD, but no single executive
    deficit is required or specific enough to define the disorder.
  mechanism_confidence: PROVISIONAL
  biological_processes:
  - preferred_term: cognition
    term:
      id: GO:0050890
      label: cognition
    modifier: ABNORMAL
  locations:
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  evidence:
  - reference: PMID:20596295
    reference_title: "The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The PFC is essential for the so-called executive functions, allowing us to
      organize and plan for the future and to inhibit responses to distractions
      in order to achieve a goal.
    explanation: >-
      The review supplies a plausible cognitive-control framework without
      showing that one executive deficit is necessary in all ADHD.
  - reference: DOI:10.1002/wps.21374
    reference_title: "Attention‐deficit/hyperactivity disorder (<scp>ADHD</scp>) in adults: evidence base, uncertainties and controversies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Key uncertainties and controversies on adult ADHD include: a) the
      possibility of late‐onset ADHD; b) the significance of emotional
      dysregulation as a core symptom; c) the definition and characterization of
      functional impairment; d) the persistence of comorbid psychiatric and
      somatic conditions after accounting for confounders; e) the relevance of
      executive dysfunction in the definition of the condition
    explanation: >-
      The current adult review explicitly identifies the definitional relevance
      of executive dysfunction as unresolved.
  downstream:
  - target: Short Attention Span
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - distinct_genetic_sa_ef
    description: >-
      Executive-attention variability can contribute to inattention, but the
      cognitive route differs among individuals.
    evidence:
    - reference: PMID:20596295
      reference_title: "The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Attention deficit/hyperactivity disorder (ADHD) is characterized by
        symptoms of inattention, impulsivity, and locomotor hyperactivity.
      explanation: >-
        The review identifies inattention as a core symptom; it does not prove a
        single executive mediator, so the edge is only partially supported.
  - target: Hyperactivity
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - distinct_genetic_sa_ef
    description: >-
      Inhibitory-control variability may contribute to hyperactive behavior, but
      this route is not universal.
    evidence:
    - reference: PMID:20596295
      reference_title: "The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Attention deficit/hyperactivity disorder (ADHD) is characterized by
        symptoms of inattention, impulsivity, and locomotor hyperactivity.
      explanation: >-
        The review identifies hyperactivity as a core symptom while leaving the
        proposed cognitive mediation provisional.
  - target: Impulsivity
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - distinct_genetic_sa_ef
    description: >-
      Inhibitory-control variability may contribute to impulsive behavior, but
      this route is not universal.
    evidence:
    - reference: PMID:20596295
      reference_title: "The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Attention deficit/hyperactivity disorder (ADHD) is characterized by
        symptoms of inattention, impulsivity, and locomotor hyperactivity.
      explanation: >-
        The review identifies impulsivity as a core symptom while leaving the
        proposed cognitive mediation provisional.

mechanistic_hypotheses:
- hypothesis_group_id: distinct_genetic_sa_ef
  hypothesis_label: Genetically distinct sustained-attention and executive-function pathways
  status: EMERGING
  description: >-
    Genomic Structural Equation Modeling identified two partially distinct latent
    genetic factors: one influencing sustained attention (SA: vigilance, lapse
    recovery cost, lapse propensity) and one influencing executive function (EF:
    processing speed, response selection, working memory). Both factors show
    unique genetic correlations with ADHD liability and other psychiatric
    outcomes, suggesting that ADHD genetic heterogeneity may partly reflect
    differential loading on SA versus EF genetic architectures. This is an
    emerging hypothesis pending replication in more diverse populations.
  evidence:
  - reference: PMID:42414552
    reference_title: Molecular genetic influences on sustained attention and executive processes and their links with psychopathology in the AFFECT study
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified two distinct latent genetic factors: one influencing EF and one
      influencing SA. Both the EF and SA factors were genetically correlated with
      cognitive and clinical phenotypes, with each latent factor uniquely linked to
      liability for psychiatric disorders, including attention-deficit/hyperactivity
      disorder.
    explanation: >-
      The study is the first multivariate GWAS characterization of SA and EF
      genetic covariance (n>20,000, enriched for MDD/bipolar), showing that genetic
      influences on sustained attention are generally distinct from those influencing
      executive function, with both contributing uniquely to ADHD genetic risk.
  - reference: PMID:42414552
    reference_title: Molecular genetic influences on sustained attention and executive processes and their links with psychopathology in the AFFECT study
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They suggest that genetic influences on sustained attention are generally
      distinct from those that influence executive function. The EF and SA factors
      show distinct patterns of genetic overlap with multiple cognitive and
      psychiatric outcomes, underscoring the need for more granular cognitive
      phenotyping to generate new insights into the genetic architecture of
      cognition and the etiology of psychopathology.
    explanation: >-
      The paper directly supports the hypothesis of genetically distinct SA and EF
      pathways and their differential psychiatric correlations.
- hypothesis_group_id: predicted_brain_multiomics_regulation
  hypothesis_label: Genetically predicted brain expression, splicing, and methylation pathways
  status: EMERGING
  description: >-
    Mendelian-randomization and mediation analyses prioritize brain-tissue
    expression, alternative-splicing, and DNA-methylation signals. These are
    statistical predictions intended to guide experimental work, not validated
    universal mechanisms, causal genes, or clinical biomarkers.
  evidence:
  - reference: DOI:10.1093/bib/bbae502
    reference_title: A multi-omics study of brain tissue transcription and DNA methylation revealing the genetic pathogenesis of ADHD
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      Finally, we also prioritized the expression of 866 genes showing
      significant causal effects, including COMMD5, ENSG00000271904, HYAL3,
      etc., within at least one brain tissue.
    explanation: >-
      The analysis prioritizes statistically predicted expression effects; the
      hypothesis label and status prevent promotion to established causal genes.
  - reference: DOI:10.1093/bib/bbae502
    reference_title: A multi-omics study of brain tissue transcription and DNA methylation revealing the genetic pathogenesis of ADHD
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      We prioritized 966 unique genes that have statistically significant causal
      AS events, within at least one of the 14 different brain tissues.
    explanation: >-
      The study reports predicted alternative-splicing signals across brain
      tissues, retained here as an emerging hypothesis.
  - reference: DOI:10.1093/bib/bbae502
    reference_title: A multi-omics study of brain tissue transcription and DNA methylation revealing the genetic pathogenesis of ADHD
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      Furthermore, through mediation analysis, 106 regulatory pathways were
      inferred where DNAm influences ADHD through gene expression or AS
      processes.
    explanation: >-
      The source itself describes the methylation pathways as inferred, so they
      are not placed in the canonical causal graph.
phenotypes:
- name: Short Attention Span
  category: Behavioral
  description: >-
    Developmentally inappropriate difficulty sustaining or directing attention,
    including distractibility and incomplete task follow-through. The required
    symptom count and expression depend on age and presentation.
  phenotype_term:
    preferred_term: Short attention span
    term:
      id: HP:0000736
      label: Short attention span
  diagnostic: true
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The pediatrician or other PCC should initiate an evaluation for ADHD for
      any child or adolescent age 4 years to the 18th birthday who presents with
      academic or behavioral problems and symptoms of inattention, hyperactivity,
      or impulsivity
    explanation: >-
      The guideline identifies inattention as a core symptom domain prompting
      ADHD evaluation; impairment and multi-setting criteria are addressed in
      the diagnosis section.
- name: Hyperactivity
  category: Behavioral
  description: >-
    Excessive motor or verbal activity, restlessness, or difficulty remaining
    still relative to developmental level and context. It is not required in the
    predominantly inattentive presentation.
  phenotype_term:
    preferred_term: Hyperactivity
    term:
      id: HP:0000752
      label: Hyperactivity
  diagnostic: true
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The pediatrician or other PCC should initiate an evaluation for ADHD for
      any child or adolescent age 4 years to the 18th birthday who presents with
      academic or behavioral problems and symptoms of inattention, hyperactivity,
      or impulsivity
    explanation: >-
      The guideline identifies hyperactivity as a core symptom domain while the
      presentation structure prevents treating it as universal.
- name: Impulsivity
  category: Behavioral
  description: >-
    Developmentally inappropriate acting, speaking, or deciding without adequate
    delay or forethought. It clusters with hyperactivity diagnostically but is
    represented separately because it is a distinct clinical feature.
  phenotype_term:
    preferred_term: Impulsivity
    term:
      id: HP:0100710
      label: Impulsivity
  diagnostic: true
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The pediatrician or other PCC should initiate an evaluation for ADHD for
      any child or adolescent age 4 years to the 18th birthday who presents with
      academic or behavioral problems and symptoms of inattention, hyperactivity,
      or impulsivity
    explanation: >-
      The guideline explicitly identifies impulsivity as a core symptom domain.

genetic: []
diagnosis:
- name: DSM-5 clinical assessment across settings
  presence: >-
    Diagnosis requires developmentally inappropriate symptoms and impairment,
    DSM-5 criteria, evidence across more than one major setting, collateral
    information, and exclusion of alternative explanations. A symptom report in
    one context alone is insufficient.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To make a diagnosis of ADHD, the PCC should determine that DSM-5 criteria
      have been met, including documentation of symptoms and impairment in more
      than 1 major setting (ie, social, academic, or occupational), with
      information obtained primarily from reports from parents or guardians,
      teachers, other school personnel, and mental health clinicians who are
      involved in the child or adolescent’s care. The PCC should also rule out
      any alternative cause
    explanation: >-
      This directly supports the pediatric multi-setting, multi-informant
      clinical diagnostic standard and alternative-cause exclusion.
- name: Structured symptom ratings and developmental history
  presence: >-
    DSM-based rating scales organize reports from relevant observers but are
    interpreted within a clinical and developmental assessment. For adolescents
    and adults, childhood onset or manifestations must be established rather
    than inferred from current symptoms alone.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To make a diagnosis of ADHD in preschool-aged children, clinicians should
      conduct a clinical interview with parents, examine and observe the child,
      and obtain information from parents and teachers through DSM-based ADHD
      rating scales.
    explanation: >-
      The guideline supports rating scales as structured inputs to, rather than
      substitutes for, a clinical assessment.
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      to meet DSM-5 criteria for ADHD, adolescents must have some reported or
      documented manifestations of inattention or hyperactivity/impulsivity
      before age 12.
    explanation: >-
      This anchors adolescent diagnosis in developmental history; adult
      assessment likewise requires careful evaluation of childhood onset.
- name: No standalone objective diagnostic test
  presence: >-
    Neuropsychological testing may clarify strengths and weaknesses, but it does
    not usually improve diagnostic accuracy. Neuroimaging, molecular findings,
    polygenic scores, and medication response are not standalone ADHD diagnostic
    tests.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The use of neuropsychological testing has not been found to improve
      diagnostic accuracy in most cases, although it may have benefit in
      clarifying the child or adolescent’s learning strengths and weaknesses.
    explanation: >-
      The guideline explicitly distinguishes diagnostic accuracy from the
      narrower value of testing for a learning profile.
  - reference: DOI:10.1002/wps.21374
    reference_title: "Attention‐deficit/hyperactivity disorder (<scp>ADHD</scp>) in adults: evidence base, uncertainties and controversies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Key uncertainties and controversies on adult ADHD include: a) the
      possibility of late‐onset ADHD; b) the significance of emotional
      dysregulation as a core symptom; c) the definition and characterization of
      functional impairment; d) the persistence of comorbid psychiatric and
      somatic conditions after accounting for confounders; e) the relevance of
      executive dysfunction in the definition of the condition; f) the use of
      objective diagnostic measures
    explanation: >-
      The adult review identifies objective measures as an unresolved area and
      does not endorse a standalone biomarker.

differential_diagnoses:
- name: Major depressive disorder
  description: >-
    Depression can cause concentration, motivation, sleep, and functional
    difficulties that mimic or coexist with ADHD. Mood course, developmental
    onset, and cross-setting persistence help determine attribution.
  disease_term:
    preferred_term: major depressive disorder
    term:
      id: MONDO:0002009
      label: major depressive disorder
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      strongly consider whether a mimicking or comorbid condition, such as
      substance use, depression, and/or anxiety, is present.
    explanation: >-
      The guideline explicitly identifies depression as a mimicking or comorbid
      condition during adolescent assessment.
- name: Generalized anxiety disorder
  description: >-
    Anxiety-related worry, arousal, avoidance, and sleep disruption can impair
    concentration or coexist with ADHD. The temporal pattern and anxiety-linked
    context should be assessed.
  disease_term:
    preferred_term: generalized anxiety disorder
    term:
      id: MONDO:0001942
      label: generalized anxiety disorder
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      strongly consider whether a mimicking or comorbid condition, such as
      substance use, depression, and/or anxiety, is present.
    explanation: >-
      The guideline explicitly includes anxiety in the mimic/comorbidity
      assessment.
- name: Specific learning disability
  description: >-
    A learning disorder can produce task-specific academic difficulty,
    avoidance, or apparent inattention and frequently coexists with ADHD.
    Assessment should distinguish a circumscribed learning profile from
    cross-setting ADHD symptoms.
  disease_term:
    preferred_term: specific learning disability
    term:
      id: MONDO:0016225
      label: specific learning disability
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the evaluation of a child or adolescent for ADHD, the PCC should include
      a process to at least screen for comorbid conditions, including emotional
      or behavioral conditions (eg, anxiety, depression, oppositional defiant
      disorder, conduct disorders, substance use), developmental conditions (eg,
      learning and language disorders, autism spectrum disorders), and physical
      conditions (eg, tics, sleep apnea)
    explanation: >-
      The guideline requires screening for learning disorders during ADHD
      evaluation.
- name: Autism spectrum disorder
  description: >-
    Autism-related social-communication differences, restricted behavior, and
    executive or sensory difficulties may overlap with ADHD symptoms, and both
    diagnoses can coexist.
  disease_term:
    preferred_term: autism spectrum disorder
    term:
      id: MONDO:0005258
      label: autism spectrum disorder
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the evaluation of a child or adolescent for ADHD, the PCC should include
      a process to at least screen for comorbid conditions, including emotional
      or behavioral conditions (eg, anxiety, depression, oppositional defiant
      disorder, conduct disorders, substance use), developmental conditions (eg,
      learning and language disorders, autism spectrum disorders), and physical
      conditions (eg, tics, sleep apnea)
    explanation: >-
      The guideline explicitly includes autism spectrum disorders in the
      developmental comorbidity screen.
- name: Obstructive sleep apnea syndrome
  description: >-
    Sleep-disordered breathing can produce daytime inattention, behavioral
    dysregulation, or sleepiness. Sleep history and physical evaluation are
    important when symptoms or risk factors suggest it.
  disease_term:
    preferred_term: obstructive sleep apnea syndrome
    term:
      id: MONDO:0007147
      label: obstructive sleep apnea syndrome
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the evaluation of a child or adolescent for ADHD, the PCC should include
      a process to at least screen for comorbid conditions, including emotional
      or behavioral conditions (eg, anxiety, depression, oppositional defiant
      disorder, conduct disorders, substance use), developmental conditions (eg,
      learning and language disorders, autism spectrum disorders), and physical
      conditions (eg, tics, sleep apnea)
    explanation: >-
      Sleep apnea is explicitly included in the physical-condition screen.
- name: Substance-related disorder
  description: >-
    Substance use can mimic or worsen attention and behavioral symptoms, alter
    treatment sequencing, and create stimulant-diversion risk, particularly in
    adolescents and adults.
  disease_term:
    preferred_term: substance-related disorder
    term:
      id: MONDO:0002494
      label: substance-related disorder
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Certain substances, such as marijuana, can have effects that mimic ADHD;
      adolescent patients may also attempt to obtain stimulant medication to
      enhance performance (ie, academic, athletic, etc) by feigning symptoms.
    explanation: >-
      The guideline directly supports both a diagnostic-mimic boundary and
      diversion-risk assessment.

treatments:
- name: Behavioral parent training and classroom intervention
  action_category: THERAPEUTIC
  therapeutic_modality: BEHAVIORAL
  description: >-
    Evidence-based parent training in behavior management and behavioral
    classroom intervention are first-line for preschool-aged children and remain
    components of multimodal care for school-age children. Availability,
    developmental level, family priorities, and functional goals shape delivery.
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: NCIT:C181743
      label: Behavioral Counseling
  target_phenotypes:
  - preferred_term: Short attention span
    term:
      id: HP:0000736
      label: Short attention span
  - preferred_term: Hyperactivity
    term:
      id: HP:0000752
      label: Hyperactivity
  - preferred_term: Impulsivity
    term:
      id: HP:0100710
      label: Impulsivity
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For preschool-aged children (age 4 years to the sixth birthday) with ADHD,
      the PCC should prescribe evidence-based behavioral PTBM and/or behavioral
      classroom interventions as the first line of treatment, if available
    explanation: >-
      The guideline makes these behavioral interventions first-line in the
      preschool age group.
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For elementary and middle school–aged children (age 6 years to the 12th
      birthday) with ADHD, the PCC should prescribe US Food and Drug
      Administration (FDA)–approved medications for ADHD, along with PTBM and/or
      behavioral classroom intervention (preferably both PTBM and behavioral
      classroom interventions).
    explanation: >-
      The school-age recommendation supports behavioral care as part of combined
      management rather than as a universal stand-alone substitute.
- name: Educational interventions and individualized school supports
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  description: >-
    School-environment changes, instructional placement, behavioral supports,
    and an individualized education or accommodation plan address functional
    impairment. Applicable supports depend on local law and the learner's
    assessed needs.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Short attention span
    term:
      id: HP:0000736
      label: Short attention span
  - preferred_term: Hyperactivity
    term:
      id: HP:0000752
      label: Hyperactivity
  - preferred_term: Impulsivity
    term:
      id: HP:0100710
      label: Impulsivity
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Educational interventions and individualized instructional supports,
      including school environment, class placement, instructional placement,
      and behavioral supports, are a necessary part of any treatment plan and
      often include an Individualized Education Program (IEP) or a rehabilitation
      plan (504 plan)
    explanation: >-
      The guideline directly supports individualized educational and school
      supports, with US plan names retained only as examples.
- name: Stimulant pharmacotherapy
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Methylphenidate- or amphetamine-class medication can reduce core ADHD
    symptoms. Pediatric use is age- and severity-dependent; preschool use has
    additional restrictions. Adult evidence supports short-term symptom benefit,
    while long-term outcomes require further study. Dose and adverse effects
    require individualized monitoring.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: methylphenidate
      term:
        id: CHEBI:6887
        label: methylphenidate
    - preferred_term: amphetamine
      term:
        id: CHEBI:2679
        label: amphetamine
  target_phenotypes:
  - preferred_term: Short attention span
    term:
      id: HP:0000736
      label: Short attention span
  - preferred_term: Hyperactivity
    term:
      id: HP:0000752
      label: Hyperactivity
  - preferred_term: Impulsivity
    term:
      id: HP:0100710
      label: Impulsivity
  target_mechanisms:
  - target: Prefrontal catecholamine neuromodulation
    description: >-
      Stimulants inhibit dopamine and norepinephrine transporters, altering
      catecholamine availability; this pharmacology does not prove a universal
      untreated catecholamine deficit.
    evidence:
    - reference: PMID:20596295
      reference_title: "The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        block both catecholamine transporters, the transporter for DA and that
        for NE.
      explanation: >-
        The review supplies the transporter-level drug action used for the
        treatment-target link.
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The evidence is particularly strong for stimulant medications; it is
      sufficient, but not as strong, for atomoxetine, extended-release
      guanfacine, and extended-release clonidine, in that order
    explanation: >-
      The pediatric guideline establishes the relative evidence base for
      stimulant and selected nonstimulant medication.
  - reference: PMID:39701638
    reference_title: "Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Stimulants and atomoxetine were the only interventions with evidence of
      beneficial effects in terms of reducing ADHD core symptoms in the short
      term, supported by both self-reported and clinician-reported ratings.
    explanation: >-
      The adult network meta-analysis supports short-term core-symptom benefit
      and prevents extrapolation to unstudied long-term outcomes.
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The PCC should titrate doses of medication for ADHD to achieve maximum
      benefit with tolerable side effects
    explanation: >-
      The recommendation supports individualized titration and tolerability
      monitoring rather than a fixed regimen.
- name: Atomoxetine pharmacotherapy
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Atomoxetine is a nonstimulant norepinephrine-transporter inhibitor with
    evidence for pediatric and short-term adult core-symptom reduction. Choice
    depends on age, comorbidity, contraindications, prior response, preferences,
    and adverse-effect monitoring.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: atomoxetine
      term:
        id: CHEBI:127342
        label: atomoxetine
  target_phenotypes:
  - preferred_term: Short attention span
    term:
      id: HP:0000736
      label: Short attention span
  - preferred_term: Hyperactivity
    term:
      id: HP:0000752
      label: Hyperactivity
  - preferred_term: Impulsivity
    term:
      id: HP:0100710
      label: Impulsivity
  target_mechanisms:
  - target: Prefrontal catecholamine neuromodulation
    description: >-
      Atomoxetine inhibits the norepinephrine transporter and thereby modulates
      prefrontal catecholamine signaling.
    evidence:
    - reference: PMID:20596295
      reference_title: "The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "selectively blocks the NE transporter."
      explanation: >-
        The review directly supports the norepinephrine-transporter target.
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The evidence is particularly strong for stimulant medications; it is
      sufficient, but not as strong, for atomoxetine, extended-release
      guanfacine, and extended-release clonidine, in that order
    explanation: >-
      The guideline supports atomoxetine while preserving the weaker evidence
      ranking relative to stimulants in pediatric care.
  - reference: PMID:39701638
    reference_title: "Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, atomoxetine was less acceptable than placebo. Medications for
      ADHD were not efficacious on additional relevant outcomes, such as quality
      of life, and evidence in the longer term is underinvestigated.
    explanation: >-
      This snippet is a caveat on acceptability and long-term evidence, not an
      efficacy statement; it qualifies rather than supports the atomoxetine
      treatment claim.
- name: Extended-release guanfacine or clonidine pharmacotherapy
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Extended-release alpha-2 adrenergic agonists are pediatric nonstimulant
    options with a smaller evidence base than stimulants. Sedation, hypotension,
    cardiovascular effects, age, formulation, and comorbidity require
    individualized assessment; this record does not generalize pediatric
    evidence to adults.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: guanfacine
      term:
        id: CHEBI:5558
        label: guanfacine
    - preferred_term: clonidine
      term:
        id: NCIT:C380
        label: Clonidine
  target_phenotypes:
  - preferred_term: Short attention span
    term:
      id: HP:0000736
      label: Short attention span
  - preferred_term: Hyperactivity
    term:
      id: HP:0000752
      label: Hyperactivity
  - preferred_term: Impulsivity
    term:
      id: HP:0100710
      label: Impulsivity
  target_mechanisms:
  - target: Prefrontal catecholamine neuromodulation
    description: >-
      Guanfacine acts at postsynaptic alpha-2A receptors in prefrontal cortex;
      the shared target node represents drug action, not a universal receptor
      defect in ADHD.
    evidence:
    - reference: PMID:20596295
      reference_title: "The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Guanfacine acts directly at postsynaptic, alpha-2A receptors in the PFC,
        where it mimics the beneficial effects of NE and strengthens PFC
        regulation of attention and behavior.
      explanation: >-
        The review provides receptor- and location-specific support for the
        guanfacine treatment-target link.
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The evidence is particularly strong for stimulant medications; it is
      sufficient, but not as strong, for atomoxetine, extended-release
      guanfacine, and extended-release clonidine, in that order
    explanation: >-
      The guideline supports both extended-release alpha-2 agonists in
      school-age pediatric care while ranking their evidence below stimulants.
clinical_trials:
- name: NCT02155608
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    Developmental pilot study of external trigeminal nerve stimulation as a
    potential nonmedication intervention for ADHD symptoms and executive
    function measures.
  target_phenotypes:
  - preferred_term: Short attention span
    term:
      id: HP:0000736
      label: Short attention span
  - preferred_term: Hyperactivity
    term:
      id: HP:0000752
      label: Hyperactivity
  evidence:
  - reference: clinicaltrials:NCT02155608
    reference_title: Developmental Pilot Study of External Trigeminal Nerve Stimulation for ADHD
    supports: SUPPORT
    snippet: >-
      The purpose of this study is to develop external Trigeminal Nerve
      Stimulation (eTNS) as a potential nonmedication treatment for
      attention-deficit/hyperactivity disorder (ADHD).
    explanation: >-
      ClinicalTrials.gov record documents a pilot neuromodulation trial
      targeting ADHD symptoms.
- name: NCT05374187
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    Multisite randomized clinical trial of external trigeminal nerve stimulation
    for ADHD in children aged 7-12 years. ClinicalTrials.gov listed the study as
    completed when the registry was rechecked on 2026-07-20; results had not yet
    been posted in the registry response.
  target_phenotypes:
  - preferred_term: Short attention span
    term:
      id: HP:0000736
      label: Short attention span
  - preferred_term: Hyperactivity
    term:
      id: HP:0000752
      label: Hyperactivity
  evidence:
  - reference: clinicaltrials:NCT05374187
    reference_title: Efficacy of External Trigeminal Nerve Stimulation for Treatment of ADHD
    supports: SUPPORT
    snippet: >-
      This study is a large multisite randomized clinical trial to asses the
      efficacy of external trigeminal nerve stimulation (TNS), a novel, minimal
      risk, non-invasive neuromodulation treatment, for ADHD in children ages
      7-12 years old (N=180).
    explanation: >-
      ClinicalTrials.gov record documents an RCT of TNS for pediatric ADHD.
datasets:
- accession: DOI:10.1093/bib/bbae502
  title: Brain tissue multi-omics Mendelian-randomization analysis for ADHD
  description: >-
    Integrative multi-omics dataset combining ADHD GWAS summary data with
    expression, alternative splicing, and DNA methylation quantitative trait
    loci across 14 brain tissues. The Mendelian-randomization and mediation
    results are predicted or inferred and require experimental validation.
  organism:
    preferred_term: Homo sapiens
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  conditions:
  - attention deficit-hyperactivity disorder
  - brain gene expression
  - alternative splicing
  - DNA methylation
  publication: DOI:10.1093/bib/bbae502
  evidence:
  - reference: DOI:10.1093/bib/bbae502
    reference_title: A multi-omics study of brain tissue transcription and DNA methylation revealing the genetic pathogenesis of ADHD
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      In this paper, a multi-omics study was conducted to investigate the causal
      effects of the transcription and the DNAm on ADHD, by integrating ADHD
      genome-wide association data with quantitative trait loci data of gene
      expression, AS, and DNAm across 14 different brain tissues.
    explanation: >-
      The publication describes a reusable integrative brain multi-omics
      analysis dataset for ADHD molecular mechanisms.
  findings:
  - statement: Mediation analysis inferred DNA-methylation pathways through gene expression or alternative splicing.
    evidence:
    - reference: DOI:10.1093/bib/bbae502
      reference_title: A multi-omics study of brain tissue transcription and DNA methylation revealing the genetic pathogenesis of ADHD
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        Furthermore, through mediation analysis, 106 regulatory pathways were
        inferred where DNAm influences ADHD through gene expression or AS
        processes.
      explanation: >-
        Captures the analysis as an inference rather than an established
        individual-level disease mechanism.
- accession: PMID:23060754
  title: "ADHD-200 Global Competition: diagnosing ADHD using personal characteristic data can outperform resting state fMRI measurements."
  description: >-
    Multi-site ADHD-control neuroimaging dataset with resting-state fMRI,
    structural MRI, demographic, IQ, and diagnostic data used in the ADHD-200
    Global Competition.
  organism:
    preferred_term: Homo sapiens
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  sample_count: 973
  conditions:
  - attention deficit-hyperactivity disorder
  - healthy control
  publication: PMID:23060754
  evidence:
  - reference: PMID:23060754
    reference_title: "ADHD-200 Global Competition: diagnosing ADHD using personal characteristic data can outperform resting state fMRI measurements."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The ADHD-200 dataset is the first publicly-available dataset with fMRI
      scans from on-the-order-of one thousand participants, including both
      psychiatric patients and healthy controls.
    explanation: >-
      The paper documents ADHD-200 as a large public neuroimaging dataset for
      ADHD and control participants.
  findings:
  - statement: ADHD-200 analyses show heterogeneity across cohorts in spontaneous brain activity.
    evidence:
    - reference: PMID:28634439
      reference_title: Inconsistency in Abnormal Brain Activity across Cohorts of ADHD-200 in Children with Attention Deficit Hyperactivity Disorder.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        These findings suggested a high heterogeneity of spontaneous brain
        activity in ADHD.
      explanation: >-
        Independent ADHD-200 analysis cautions that multi-site pooled
        neuroimaging findings vary across cohorts.
clinical_burden:
  burden_level: VARIABLE
  rationale: >-
    ADHD can impose persistent educational, occupational, interpersonal, safety,
    and mental-health burden, but severity, presentation, comorbidity, support,
    and course vary widely. No single low, moderate, or high category represents
    the full population.
  evidence:
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      patients with ADHD, whether treated or not, are at increased risk for early
      death, suicide, and increased psychiatric comorbidity, particularly
      substance use disorders.
    explanation: >-
      The guideline documents important long-term risks at the population level;
      these associations do not determine an individual's outcome.
  - reference: PMID:31570648
    reference_title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They also have lower educational achievement than those without ADHD
    explanation: >-
      Population-level educational outcomes support clinically meaningful
      burden while the rationale preserves individual variability.
  - reference: DOI:10.1002/wps.21374
    reference_title: "Attention‐deficit/hyperactivity disorder (<scp>ADHD</scp>) in adults: evidence base, uncertainties and controversies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additionally, up to 70% of individuals with childhood‐onset ADHD continue
      to experience impairing symptoms as adults, even if they no longer meet
      the criteria for a formal diagnosis.
    explanation: >-
      Persistence of impairing symptoms beyond formal diagnostic threshold
      supports longitudinal burden and variability.
discussions:
- discussion_id: interpretation_polygenic_not_single_gene
  prompt: >-
    Should ADHD be represented as a Mendelian disorder with a causal gene list?
  kind: INTERPRETATION
  status: RESOLVED
  attaches_to:
  - pathophysiology#Polygenic neurodevelopmental liability
  - diagnosis#No standalone objective diagnostic test
  rationale: >-
    Large association and family-trio studies support inherited polygenic
    susceptibility. Associated loci and predicted molecular targets are not
    deterministic causal genes and do not justify disease-level gene records or
    diagnostic genetic testing.
  evidence:
  - reference: PMID:30478444
    reference_title: Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Common genetic variants contribute substantially to ADHD susceptibility,
      but no variants have been robustly associated with ADHD.
    explanation: >-
      The GWAS frames ADHD in terms of distributed susceptibility rather than a
      single causal gene.
- discussion_id: interpretation_group_findings_not_biomarkers
  prompt: >-
    Should group-level imaging or multi-omics findings be used as ADHD
    diagnostic biomarkers?
  kind: INTERPRETATION
  status: RESOLVED
  attaches_to:
  - pathophysiology#Distributed neural-network differences
  - mechanistic_hypotheses#predicted_brain_multiomics_regulation
  - diagnosis#No standalone objective diagnostic test
  rationale: >-
    Imaging effects are heterogeneous and method-sensitive, while multi-omics
    results are statistical predictions. Neither evidence stream establishes a
    sufficiently validated individual diagnostic test.
  evidence:
  - reference: PMID:28634439
    reference_title: Inconsistency in Abnormal Brain Activity across Cohorts of ADHD-200 in Children with Attention Deficit Hyperactivity Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The standardized effect size was rather small. These findings suggested a
      high heterogeneity of spontaneous brain activity in ADHD.
    explanation: >-
      Small, inconsistent cohort effects argue against an individual functional
      imaging biomarker.
  - reference: DOI:10.1093/bib/bbae502
    reference_title: A multi-omics study of brain tissue transcription and DNA methylation revealing the genetic pathogenesis of ADHD
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      Our research findings provide guidance for future experimental studies on
      the molecular mechanisms of ADHD development
    explanation: >-
      The authors position their results as guidance for future experiments,
      consistent with hypothesis rather than biomarker status.
- discussion_id: gap_long_term_and_adult_intervention_outcomes
  prompt: >-
    Which interventions produce durable improvements in adult functioning and
    quality of life, and for whom?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - treatments#Stimulant pharmacotherapy
  - treatments#Atomoxetine pharmacotherapy
  rationale: >-
    Short-term symptom evidence is stronger than evidence for durable adult
    functional benefit, and nonpharmacologic adult results vary by rater.
  evidence:
  - reference: PMID:39701638
    reference_title: "Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Medications for ADHD were not efficacious on additional relevant outcomes,
      such as quality of life, and evidence in the longer term is
      underinvestigated.
    explanation: >-
      The adult network meta-analysis directly identifies the long-term and
      functional-outcome evidence gap.

references:
- reference: PMID:31570648
  title: "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents."
- reference: DOI:10.1002/wps.21374
  title: "Attention‐deficit/hyperactivity disorder (<scp>ADHD</scp>) in adults: evidence base, uncertainties and controversies"
- reference: PMID:30478444
  title: Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder.
- reference: DOI:10.1038/s41380-022-01863-6
  title: Genetic nurture versus genetic transmission of risk for ADHD traits in the Norwegian Mother, Father and Child Cohort Study
- reference: DOI:10.1038/s41380-023-02173-1
  title: "White matter alterations in Attention-Deficit/Hyperactivity Disorder (ADHD): a systematic review of 129 diffusion imaging studies with meta-analysis"
- reference: PMID:28634439
  title: Inconsistency in Abnormal Brain Activity across Cohorts of ADHD-200 in Children with Attention Deficit Hyperactivity Disorder.
- reference: PMID:20596295
  title: "The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex."
- reference: DOI:10.1093/bib/bbae502
  title: A multi-omics study of brain tissue transcription and DNA methylation revealing the genetic pathogenesis of ADHD
- reference: PMID:39701638
  title: "Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis."
- reference: PMID:23060754
  title: "ADHD-200 Global Competition: diagnosing ADHD using personal characteristic data can outperform resting state fMRI measurements."
- reference: clinicaltrials:NCT02155608
  title: Developmental Pilot Study of External Trigeminal Nerve Stimulation for ADHD
- reference: clinicaltrials:NCT05374187
  title: Efficacy of External Trigeminal Nerve Stimulation for Treatment of ADHD

notes: >-
  This entry deliberately models ADHD as a heterogeneous polygenic
  neurodevelopmental disorder. It does not assign causal-gene records, encode a
  universal catecholamine deficiency, or treat group-level imaging,
  multi-omics, neuropsychological, or treatment-response findings as diagnostic
  biomarkers. DSM-5 presentations are clinical symptom patterns rather than
  discrete biological subtypes. Pediatric management recommendations are scoped
  to the AAP guideline's ages 4-18; adult evidence and uncertainties are cited
  separately. The two eTNS records are trials, not endorsements of eTNS as
  established treatment.
📚

References & Deep Research

References

12
PMID:31570648
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.
No top-level findings curated for this source.
DOI:10.1002/wps.21374
Attention‐deficit/hyperactivity disorder (<scp>ADHD</scp>) in adults: evidence base, uncertainties and controversies
No top-level findings curated for this source.
PMID:30478444
Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder.
No top-level findings curated for this source.
DOI:10.1038/s41380-022-01863-6
Genetic nurture versus genetic transmission of risk for ADHD traits in the Norwegian Mother, Father and Child Cohort Study
No top-level findings curated for this source.
DOI:10.1038/s41380-023-02173-1
White matter alterations in Attention-Deficit/Hyperactivity Disorder (ADHD): a systematic review of 129 diffusion imaging studies with meta-analysis
No top-level findings curated for this source.
PMID:28634439
Inconsistency in Abnormal Brain Activity across Cohorts of ADHD-200 in Children with Attention Deficit Hyperactivity Disorder.
No top-level findings curated for this source.
PMID:20596295
The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex.
No top-level findings curated for this source.
DOI:10.1093/bib/bbae502
A multi-omics study of brain tissue transcription and DNA methylation revealing the genetic pathogenesis of ADHD
No top-level findings curated for this source.
PMID:39701638
Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis.
No top-level findings curated for this source.
PMID:23060754
ADHD-200 Global Competition: diagnosing ADHD using personal characteristic data can outperform resting state fMRI measurements.
No top-level findings curated for this source.
clinicaltrials:NCT02155608
Developmental Pilot Study of External Trigeminal Nerve Stimulation for ADHD
No top-level findings curated for this source.
clinicaltrials:NCT05374187
Efficacy of External Trigeminal Nerve Stimulation for Treatment of ADHD
No top-level findings curated for this source.

Deep Research

2
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 40 citations 2026-04-24T17:14:09.009479

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Attention Deficit-Hyperactivity Disorder
  • MONDO ID: (if available)
  • Category: Psychiatric

Research Objectives

Please provide a comprehensive research report on Attention Deficit-Hyperactivity Disorder covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: Attention-Deficit/Hyperactivity Disorder (ADHD)

Scope and evidence base (this run)

This report synthesizes evidence retrieved via tool-based searches in peer‑reviewed literature and clinical-trial registries, prioritizing 2023–2024 where available. Some requested ontology identifiers (MONDO/MeSH/OMIM/Orphanet) and some phenotype/QoL/model-organism details could not be retrieved in this run and are explicitly flagged as gaps.

Domain Key finding (with quantitative values) Population/setting Source (first author, journal, year) Publication date/month PMID URL
Epidemiology/Burden In China, age-standardized ADHD prevalence increased by 9.86% from 1990 to 2021 (AAPC 0.272%, 95% CI 0.173–0.372), while age-standardized DALY rates increased by 10.15% (AAPC 0.262%, 95% CI 0.160–0.364); adolescents 10–14 years had prevalence 5,727.28/100,000 and DALY rate 70.55/100,000 (li2025theburdenof pages 1-2, li2025theburdenof pages 2-4) GBD 2021-based China national burden analysis, children/adolescents Li, Frontiers in Psychiatry, 2025 Mar 2025 https://doi.org/10.3389/fpsyt.2025.1532156
Epidemiology/Burden In 2021 China burden estimates, males had higher age-standardized prevalence (3,045.272/100,000) and DALYs (37.291/100,000) than females (1,215.746/100,000; 14.848/100,000), but female rates rose faster over time (li2025theburdenof pages 2-4) China children/adolescents, sex-stratified burden Li, Frontiers in Psychiatry, 2025 Mar 2025 https://doi.org/10.3389/fpsyt.2025.1532156
Epidemiology/Burden In a UK birth cohort, 3.0% of participants were classified with childhood ADHD problems at age 7 (thapar2023childhoodattentiondeficithyperactivity pages 1-2) National Child Development Study, UK population cohort, n=8,016 with follow-up Thapar, British Journal of Psychiatry, 2023 Jul 2023 https://doi.org/10.1192/bjp.2023.90
Genetics In 19,506 genotyped mother-father-offspring trios (child ADHD ratings in n=9,454), associations between maternal and paternal polygenic scores and child ADHD traits dropped markedly after adjustment for child polygenic score (pΔβ=9.95×10−17 maternal; 1.48×10−14 paternal), supporting genetic transmission over genetic nurture (pingault2023geneticnurtureversus pages 1-2) Norwegian Mother, Father and Child Cohort Study trios Pingault, Molecular Psychiatry, 2023 Nov 2023 https://doi.org/10.1038/s41380-022-01863-6
Genetics ADHD GWAS sample included 38,691 cases and 186,843 controls; genetic correlation with cannabis use disorder was rg=0.57 (SE 0.04) and with cannabis use rg=0.20 (SE 0.04); 36 genome-wide significant ADHD–CUD loci identified, including signals near METTL15 and FOXP2 (nielsen2024sharedgeneticsof pages 2-3, nielsen2024sharedgeneticsof pages 1-2) Cross-disorder GWAS/meta-analysis Nielsen, Nature Mental Health, 2024 Jul 2024 https://doi.org/10.1038/s44220-024-00277-3
Genetics Multi-omics integration across 14 GTEx v8 brain tissues prioritized 866 genes with significant expression effects and 966 genes with significant alternative-splicing effects; 106 regulatory pathways suggested DNA methylation influences ADHD through expression or splicing (wang2024amultiomicsstudy pages 1-2) Brain-tissue eQTL/sQTL/mQTL + ADHD GWAS integration Wang, Briefings in Bioinformatics, 2024 Sep 2024 https://doi.org/10.1093/bib/bbae502
Disease information / diagnostics DSM-5-TR and ICD-11 both require symptoms before age 12, cross-situational impairment, and duration ≥6 months, but DSM-5-TR specifies thresholds (6 symptoms per domain in children; 5 if age ≥17) while ICD-11 relies on clinician judgment and “several symptoms,” increasing potential heterogeneity (gomez2023differencesbetweendsm5tr pages 3-4, gomez2023differencesbetweendsm5tr pages 5-7) Diagnostic classification comparison Gomez, World Journal of Psychiatry, 2023 May 2023 https://doi.org/10.5498/wjp.v13.i5.138
Outcomes/Safety Childhood ADHD problems predicted higher mid-life cardiovascular risk: BMI +0.92 kg/m², systolic BP +3.5 mmHg, diastolic BP +2.2 mmHg, triglycerides +0.24 mol/L, and current smoking OR 1.6; no association with LDL cholesterol (thapar2023childhoodattentiondeficithyperactivity pages 1-2) UK prospective population cohort, childhood ADHD assessed at 7 years and CVD risk at 44/45 years Thapar, British Journal of Psychiatry, 2023 Jul 2023 https://doi.org/10.1192/bjp.2023.90
Outcomes/Safety Among 217,192 individuals aged 1–24 with ADHD, medication episodes were associated with reduced all-cause mortality (aHR 0.61, 95% CI 0.48–0.76), lower injury-related ED visits (aHR 0.75, 0.74–0.77), and lower injury-related hospitalizations (aHR 0.71, 0.68–0.75) versus non-medication periods (vasiliadis2024adhdmedicationsuse pages 1-2) Quebec population-based retrospective cohort, 2000–2021 Vasiliadis, Translational Psychiatry, 2024 Feb 2024 https://doi.org/10.1038/s41398-024-02825-y
Outcomes/Safety In 278,027 Swedish individuals with ADHD, each additional year of ADHD medication use was associated with a 4% increased CVD risk (AOR 1.04, 95% CI 1.03–1.05); compared with nonuse, AORs were 1.27 for 3–5 years and 1.23 for >5 years; strongest signals were for hypertension (AOR 1.72 for 3–5 years; 1.80 for >5 years) (zhang2024attentiondeficithyperactivitydisordermedications pages 1-2, zhang2024attentiondeficithyperactivitydisordermedications pages 6-7) Swedish nested case-control study with incident CVD cases Zhang, JAMA Psychiatry, 2024 Feb 2024 https://doi.org/10.1001/jamapsychiatry.2023.4294
Outcomes/Safety Adults with diagnosed ADHD in UK primary care had reduced life expectancy of 6.78 years for males (95% CI 4.50–9.11) and 8.64 years for females (95% CI 6.55–10.91); only ~0.32% of cohort adults carried an ADHD diagnosis (onions2025lifeexpectancyand pages 1-2) UK matched cohort: 30,039 adults with diagnosed ADHD vs 300,390 matched controls O'Nions, British Journal of Psychiatry, 2025 Jan 2025 https://doi.org/10.1192/bjp.2024.199
Treatment innovations Recent innovation review highlights viloxazine ER, the first FDA-approved transdermal amphetamine patch, digital therapeutics, and trigeminal nerve stimulation (TNS) as new options to personalize ADHD care; TNS initial effect sizes were described as comparable to nonstimulant medications, but long-term cost-effectiveness and acceptability remain uncertain (baweja2024fromconsensusstatement pages 1-2, baweja2024fromconsensusstatement pages 10-11) Review of recent innovations in ADHD care Baweja, Journal of Child and Adolescent Psychopharmacology, 2024 May 2024 https://doi.org/10.1089/cap.2024.0022
Treatment innovations TNS practical/safety summary: >1 year of use had not indicated significant safety concerns; stimulation can be reduced in 0.2 mA steps for adverse effects, and no published studies had evaluated TNS combined with ADHD medications at the time of review (baweja2024fromconsensusstatement pages 9-10) Pediatric ADHD device-based treatment implementation Baweja, Journal of Child and Adolescent Psychopharmacology, 2024 May 2024 https://doi.org/10.1089/cap.2024.0022
Treatment innovations In a 4-week digital therapy study of 52 children aged 6–12, SNAP-IV parent scores improved (P<0.001) and TOVA-ACS improved (P<0.05); parental acceptance was 100%, average compliance 95%, and device-related adverse reactions occurred in 7.69% with no serious adverse events (huang2024clinicalstudyon pages 1-2) Single-center clinical study, Wuhan Children’s Hospital, stable-treatment children with ADHD Huang, Scientific Reports, 2024 Oct 2024 https://doi.org/10.1038/s41598-024-73934-3

Table: This table compiles quantitative ADHD findings from the retrieved evidence across epidemiology, genetics, outcomes/safety, diagnostics, and treatment innovation. It is useful as a high-density reference for populating a disease knowledge base with recent, citable statistics and implementation-relevant results.

1. Disease information

1.1 Concise overview

Attention‑deficit/hyperactivity disorder (ADHD) is a neurodevelopmental/psychiatric condition characterized by persistent, developmentally inappropriate patterns of inattention and/or hyperactivity–impulsivity that cause impairment across settings (e.g., home/school/work) and typically begin in childhood. Both DSM‑5‑TR and ICD‑11 require: symptoms beginning before age 12, duration of at least 6 months, cross‑situational presence, and clinically significant impairment. (gomez2023differencesbetweendsm5tr pages 3-4)

1.2 Key identifiers (availability in retrieved evidence)

  • DSM-5-TR: ADHD diagnostic entity with presentations (combined; predominantly inattentive; predominantly hyperactive/impulsive). (gomez2023differencesbetweendsm5tr pages 3-4)
  • ICD-11: ADHD diagnostic entity with similar presentations but different operationalization (see below). (gomez2023differencesbetweendsm5tr pages 3-4)
  • ICD-10 historical: “hyperkinetic disorder” (HKD) as a narrower/severe construct; ICD‑11 broadened to include less severe presentations. (gomez2023differencesbetweendsm5tr pages 1-3)
  • ICD/MeSH/MONDO/OMIM/Orphanet IDs: Not retrievable from the tools/evidence in this run; therefore not asserted here.

1.3 Synonyms / alternative names

  • “Attention deficit hyperactivity disorder” / “Attention-deficit/hyperactivity disorder” (standard in DSM‑5‑TR and ICD‑11). (gomez2023differencesbetweendsm5tr pages 3-4)
  • “Hyperkinetic disorder” (ICD‑10 legacy terminology). (gomez2023differencesbetweendsm5tr pages 1-3)

1.4 Data provenance

The evidence here is predominantly aggregated disease-level resources: population cohorts, administrative‑data pharmacoepidemiology, and multi‑cohort genetic studies, rather than EHR case reports. (li2025theburdenof pages 2-4, vasiliadis2024adhdmedicationsuse pages 1-2, zhang2024attentiondeficithyperactivitydisordermedications pages 1-2)

2. Etiology

2.1 Disease causal factors (current understanding)

ADHD etiology is multifactorial and polygenic, with substantial common-variant contribution and extensive pleiotropy with other psychiatric/behavioral traits.

A key recent within‑family study (MoBa trios) supports that much observed parent–child association for ADHD traits is attributable to genetic transmission rather than environmentally mediated “genetic nurture.” Specifically, in 19,506 genotyped mother‑father‑offspring trios (child ADHD ratings available for n=9,454 at age 8), associations between maternal/paternal polygenic scores and child ADHD traits decreased markedly after adjusting for the child polygenic score (maternal pΔβ=9.95×10−17; paternal pΔβ=1.48×10−14). (pingault2023geneticnurtureversus pages 1-2)

Direct quote (abstract): Pingault et al. conclude that “the intergenerational transmission of risk for ADHD traits is largely explained by the transmission of genetic variants from parents to offspring rather than by genetic nurture.” (pingault2023geneticnurtureversus pages 4-5)

2.2 Risk factors (genetic)

Cross-disorder and comorbidity genetics (2024)

A 2024 Nature Mental Health study analyzed shared genetics between ADHD, cannabis use disorder (CUD), and cannabis use (CU), with large GWAS sample sizes (ADHD: 38,691 cases and 186,843 controls; CUD: 42,281 cases and 843,744 controls; CU: n=162,082). Genetic correlation was substantial for ADHD–CUD (rg=0.57, SE 0.04) and modest for ADHD–CU (rg=0.20, SE 0.04). (nielsen2024sharedgeneticsof pages 2-3)

The same study identified genome‑wide significant cross‑phenotype loci and highlighted candidate genes near signals including METTL15 and FOXP2 for ADHD–CUD. (nielsen2024sharedgeneticsof pages 2-3)

Direct quote (abstract): the paper frames aims including “Shared genetics of ADHD, cannabis use disorder and cannabis use” and provides rg estimates and sample sizes in the abstract excerpted here. (nielsen2024sharedgeneticsof pages 2-3)

Multi-omics (2024) linking genetics to brain tissue regulation

A 2024 study integrated ADHD GWAS with brain-tissue eQTL/sQTL/mQTL data across 14 GTEx v8 brain tissues using two-sample Mendelian randomization. It prioritized 866 genes with significant expression effects and 966 unique genes with significant alternative-splicing effects, and inferred 106 regulatory pathways in which DNA methylation may influence ADHD through expression or splicing. (wang2024amultiomicsstudy pages 1-2)

Direct quote (abstract): “we also prioritized the expression of 866 genes … [and] 966 unique genes that have statistically significant causal AS events … [and] 106 regulatory pathways … where DNAm influences ADHD through gene expression or AS processes.” (wang2024amultiomicsstudy pages 1-2)

2.3 Environmental risk factors / protective factors / GxE

Environmental exposures and gene–environment interaction are widely discussed in the broader ADHD literature, but the specific, high‑quality primary evidence for individual environmental risk/protective factors was not retrieved in this run. Consequently, no specific environmental causal claims are asserted here.

3. Phenotypes

3.1 Core phenotypes (symptoms/behavioral)

The core symptom domains are: * Inattention and hyperactivity/impulsivity (DSM‑5‑TR and ICD‑11). (gomez2023differencesbetweendsm5tr pages 3-4)

DSM‑5‑TR enumerates 9 inattention and 9 hyperactivity/impulsivity symptoms with symptom-count thresholds; ICD‑11 includes additional/split items (11 and 11) and differs in operationalization. (gomez2023differencesbetweendsm5tr pages 3-4, gomez2023differencesbetweendsm5tr pages 1-3)

3.2 Developmental features

ICD‑11 provides more explicit developmental variants (e.g., childhood fidgeting vs adult “mental restlessness”), and emphasizes that symptom expression can vary by setting and be less evident during stimulating activities. (gomez2023differencesbetweendsm5tr pages 3-4)

3.3 Suggested HPO terms (provisional; not exhaustively validated in retrieved evidence)

Because HPO mappings were not retrieved from an ontology source in this run, the following are conservative suggestions aligned to the symptom domains documented above: * Inattention → HP:0000736 (Short attention span) (suggested) * Hyperactivity → HP:0000752 (Hyperactivity) (suggested) * Impulsivity → HP:0000741 (Impulsivity) (suggested)

3.4 Frequency among affected individuals / QoL impact

Not retrievable from the evidence in this run (e.g., no systematic phenotype frequency table, EQ‑5D/SF‑36 outcomes). Not asserted.

4. Genetic / molecular information

4.1 “Causal genes” vs polygenic architecture

The retrieved evidence supports ADHD as highly polygenic, with risk distributed across many variants, rather than a single-gene Mendelian disorder. (pingault2023geneticnurtureversus pages 1-2, nielsen2024sharedgeneticsof pages 1-2)

4.2 Example genes/loci implicated in recent analyses (not clinical diagnostic genes)

  • ADHD–CUD cross‑disorder loci highlighted near METTL15 and FOXP2 (GWAS cross‑trait). (nielsen2024sharedgeneticsof pages 2-3)
  • Multi‑omics prioritized gene examples include COMMD5, HYAL3, PPP1R16A, TREM2 (tissue-specific MR/mediation results). (wang2024amultiomicsstudy pages 1-2)

4.3 Variant classification, allele frequency, somatic/germline

ClinVar/gnomAD/COSMIC-derived variant-level evidence was not retrieved in this run; not asserted.

4.4 Epigenetics

Evidence for DNA methylation as a mediator in brain tissues is provided by the multi‑omics mediation analysis (106 pathways) integrating mQTL with eQTL/sQTL and ADHD GWAS. (wang2024amultiomicsstudy pages 1-2)

5. Environmental information

Specific toxins, lifestyle factors, or infectious triggers were not supported by retrieved primary evidence in this run; not asserted.

6. Mechanism / pathophysiology

6.1 Current mechanistic understanding supported by retrieved evidence

Diagnostic‑framework implications for underlying structure

Gomez et al. (2023) note that DSM‑5‑TR implies a two‑factor structure (inattention vs combined hyperactivity/impulsivity) but that empirical latent-structure work often supports three-factor (inattention; hyperactivity; impulsivity) or bifactor models emphasizing impulsivity. They also emphasize the lack of validated ICD‑11 rating scales and the absence of reliable biomarkers for ADHD. (gomez2023differencesbetweendsm5tr pages 4-5, gomez2023differencesbetweendsm5tr pages 5-7)

Regulatory mechanisms in brain tissues

The 2024 brain multi‑omics MR study provides mechanistic hypotheses in which genetically influenced gene expression, alternative splicing, and DNA methylation in brain tissues contribute to ADHD liability, including mediated DNAm→expression/splicing regulatory pathways. (wang2024amultiomicsstudy pages 1-2)

6.2 Causal chain (supported, high-level)

A conservative chain consistent with retrieved evidence is: 1) Distributed inherited genetic risk transmitted from parents → 2) tissue-specific regulatory effects in brain (expression/splicing/methylation) → 3) altered neurodevelopmental/neurocognitive processes (inferred, not directly phenotyped in these sources) → 4) persistent inattention and/or hyperactivity–impulsivity with impairment across settings. (wang2024amultiomicsstudy pages 1-2, pingault2023geneticnurtureversus pages 1-2, gomez2023differencesbetweendsm5tr pages 3-4)

6.3 Suggested ontology mappings (high-level)

  • UBERON (anatomy; suggested): prefrontal cortex / frontal cortex; basal ganglia/striatum (not directly asserted in the retrieved evidence; included only as common ADHD neurocircuit targets—should be validated against additional sources).
  • GO biological processes (suggested): regulation of transcription; RNA splicing; DNA methylation; synaptic signaling (as these categories are implicated by multi‑omics gene regulation). (wang2024amultiomicsstudy pages 1-2)
  • CL (cell types; suggested): neurons/glia (cell-type specific enrichments are referenced generally in later review excerpts but not quantified in the retrieved text snippets; should be confirmed with additional primary sources). (cortese2025attention‐deficithyperactivitydisorder(adhd) pages 10-10)

7. Anatomical structures affected

Direct anatomical localization evidence (imaging, lesion, or region-specific pathology) was not retrieved in this run, aside from the fact that the multi‑omics study explicitly focuses on brain tissues across 14 regions (GTEx v8). (wang2024amultiomicsstudy pages 1-2)

Suggested (needs confirmation from dedicated neuroimaging literature): CNS structures involved in attention/executive function and motor inhibition.

8. Temporal development

8.1 Onset

Both DSM‑5‑TR and ICD‑11 require some symptoms before age 12, and symptoms should persist for at least 6 months. (gomez2023differencesbetweendsm5tr pages 3-4)

8.2 Course / progression

Cortese et al. note that hyperactive/impulsive symptoms tend to decrease more than inattentive symptoms, such that older adolescents/adults often present more prominently with inattentive symptoms. (cortese2025attention‐deficithyperactivitydisorder(adhd) pages 3-4)

9. Inheritance and population

9.1 Inheritance pattern

The evidence in this run supports ADHD as a polygenic, multifactorial condition with predominant genetic transmission effects in family-based polygenic analyses. (pingault2023geneticnurtureversus pages 1-2)

9.2 Epidemiology and burden (recent quantitative data retrieved)

A China-focused GBD analysis (1990–2021) reported increasing age-standardized ADHD burden despite decreasing crude prevalence; adolescents 10–14 years bore the highest burden with prevalence 5,727.28/100,000 and DALY rate 70.55/100,000 (about twice the global average, per authors). (li2025theburdenof pages 1-2)

Direct quote (abstract excerpt): “Crude ADHD prevalence declined by 21.17% … yet age-standardized prevalence increased by 9.86% … Similarly, age-standardized DALY rates rose by 10.15% … Adolescents aged 10–14 years bore the highest burden …” (li2025theburdenof pages 1-2)

A UK 1958 birth cohort study used a childhood ADHD-problem screen and found 3.0% classified with childhood ADHD problems among 8,016 participants with childhood and midlife biomedical data. (thapar2023childhoodattentiondeficithyperactivity pages 1-2)

Global prevalence estimates for 2023–2024 were not retrieved in this run; therefore not asserted.

10. Diagnostics

10.1 Diagnostic criteria (DSM‑5‑TR vs ICD‑11)

  • Shared core requirements: symptoms before age 12; persistence ≥6 months; impairment; cross-situational presence. (gomez2023differencesbetweendsm5tr pages 3-4)
  • DSM‑5‑TR operationalization: explicit symptom lists and numeric thresholds (children: ≥6 inattention and/or ≥6 hyperactivity/impulsivity; age ≥17: ≥5 per domain). (gomez2023differencesbetweendsm5tr pages 3-4)
  • ICD‑11 operationalization: similar presentations but relies on clinician judgment and “several symptoms,” without fixed symptom-count thresholds, potentially increasing diagnostic heterogeneity; also includes some additional/split symptom items vs DSM. (gomez2023differencesbetweendsm5tr pages 3-4, gomez2023differencesbetweendsm5tr pages 1-3)

10.2 Rating scales / biomarkers

Gomez et al. emphasize a lack of validated ICD‑11–based ADHD rating scales and that there are no reliable biomarkers for ADHD currently. (gomez2023differencesbetweendsm5tr pages 4-5, gomez2023differencesbetweendsm5tr pages 5-7)

Differential diagnosis evidence was not retrieved in this run.

11. Outcomes / prognosis

11.1 Cardiovascular risk factors (life course)

In a UK prospective cohort, childhood ADHD problems at age 7 predicted adverse cardiovascular risk factor profiles at age 44/45: higher BMI (+0.92 kg/m²), systolic BP (+3.5 mmHg), diastolic BP (+2.2 mmHg), triglycerides (+0.24 mol/L), and current smoking (OR 1.6), but not LDL cholesterol. (thapar2023childhoodattentiondeficithyperactivity pages 1-2)

11.2 Mortality and life expectancy

A UK primary-care matched cohort study estimated reduced life expectancy in diagnosed adult ADHD: 6.78 years lower for males and 8.64 years lower for females, compared with matched controls. (onions2025lifeexpectancyand pages 1-2)

11.3 Medication-associated outcomes: injuries and mortality (youth)

A Quebec population-based cohort (2000–2021; n=217,192 aged 1–24) found medication episodes were associated with lower all-cause mortality (aHR 0.61) and reduced unintentional injury requiring ED visit (aHR 0.75) or hospitalization (aHR 0.71) compared to non-medication periods. (vasiliadis2024adhdmedicationsuse pages 1-2)

11.4 Medication-associated cardiovascular risk (long-term)

A Swedish nested case-control study (incident CVD cases among 278,027 individuals with ADHD) reported that each additional year of ADHD medication exposure was associated with ~4% increased CVD risk (AOR 1.04, 95% CI 1.03–1.05), and longer cumulative exposure was associated with higher odds of hypertension and arterial disease. (zhang2024attentiondeficithyperactivitydisordermedications pages 1-2, zhang2024attentiondeficithyperactivitydisordermedications pages 6-7)

12. Treatment

12.1 Current applications and real-world implementations (2023–2024 emphasis)

A 2024 review highlights newer options beyond standard oral stimulants/non‑stimulants, including viloxazine extended release, the first transdermal amphetamine patch, digital therapeutics, and trigeminal nerve stimulation (TNS), framing these as tools for personalization and access. (baweja2024fromconsensusstatement pages 1-2)

Digital therapeutics (example: attention training)

A 2024 Scientific Reports clinical study evaluated “MindPro1” attention‑training software in 52 children (6–12 years) over 4 weeks with stable background treatment. It reported improvement on SNAP‑IV parent scores (P<0.001) and TOVA attention metrics (P<0.05), with 100% parental acceptance and 95% mean compliance, and mild transient adverse reactions in 7.69% without serious adverse events. (huang2024clinicalstudyon pages 1-2)

Direct quote (abstract): “After 4 weeks … the SNAP-IV parent score improved (P < 0.001) … the TOVA-ACS score improved (P < 0.05) … acceptance rate … 100% … average compliance rate … 95% … 4 cases (7.69%) of adverse reactions … no serious adverse events.” (huang2024clinicalstudyon pages 1-2)

Trigeminal nerve stimulation (TNS)

The innovation review describes TNS as “well-tolerated” with early trial effect sizes comparable to nonstimulants, and provides practical use considerations (e.g., sensation is forehead tingling; single-use electrodes; dose adjustments for adverse effects). (baweja2024fromconsensusstatement pages 1-2, baweja2024fromconsensusstatement pages 9-10)

A cropped image of a practical troubleshooting/implementation table for TNS (Table 2) was retrieved from this review and can be used as a visual evidence item. (baweja2024fromconsensusstatement media baf871c0)

12.2 Treatment safety tradeoffs (recent evidence)

Real-world studies provide a nuanced picture: medication exposure episodes may reduce injuries and mortality in youth (Quebec cohort) (vasiliadis2024adhdmedicationsuse pages 1-2), whereas long-term cumulative exposure may be associated with elevated CVD risk, particularly hypertension/arterial disease (Swedish nested case-control). (zhang2024attentiondeficithyperactivitydisordermedications pages 1-2, zhang2024attentiondeficithyperactivitydisordermedications pages 6-7)

12.3 Suggested MAXO terms (provisional)

  • Pharmacotherapy (stimulant and non‑stimulant medication treatment)
  • Cognitive training / digital therapeutic intervention
  • Neurostimulation therapy (e.g., trigeminal nerve stimulation)

Specific MAXO IDs were not retrieved in this run.

13. Prevention

Primary/secondary/tertiary prevention evidence (e.g., risk-factor modification trials, screening program evaluations) was not retrieved in this run and is not asserted.

14. Other species / natural disease

Not retrievable from the evidence in this run.

15. Model organisms

Model-organism evidence (mouse/rat/zebrafish/Drosophila, iPSC systems) was not retrieved in this run; not asserted.

Expert analysis and interpretation (evidence-grounded)

1) Diagnostic operationalization matters for research comparability: DSM‑5‑TR’s algorithmic thresholds vs ICD‑11’s clinician-judgment approach can change case definitions and affect reliability and cross-study comparability; Gomez et al. explicitly raise concerns about ICD‑11 threshold vagueness and lack of validated rating scales. (gomez2023differencesbetweendsm5tr pages 4-5, gomez2023differencesbetweendsm5tr pages 5-7) 2) Genetic evidence supports transmission-dominant intergenerational risk in a large trio design, cautioning against interpreting parental exposures as purely environmental without genetically informed designs. (pingault2023geneticnurtureversus pages 1-2) 3) Real-world benefit–risk is multi-domain: pharmacoepidemiology suggests potential reductions in injuries/mortality during treated periods in youth (vasiliadis2024adhdmedicationsuse pages 1-2) while also indicating possible long-term cardiovascular risks with cumulative exposure (zhang2024attentiondeficithyperactivitydisordermedications pages 1-2). These findings support the clinical practice emphasis on individualized decision making and monitoring. (zhang2024attentiondeficithyperactivitydisordermedications pages 1-2)

References (URLs with publication dates)

Key URLs and dates are provided inline and in the summary table artifact. The primary evidence base in this run includes: Gomez 2023 (World J Psychiatry; May 2023), Thapar 2023 (Br J Psychiatry; Jul 2023), Pingault 2023 (Molecular Psychiatry; Nov 2023), Zhang 2024 (JAMA Psychiatry; Feb 2024), Vasiliadis 2024 (Transl Psychiatry; Feb 2024), Nielsen 2024 (Nature Mental Health; Jul 2024), Wang 2024 (Briefings in Bioinformatics; Sep 2024), Huang 2024 (Scientific Reports; Oct 2024), Baweja 2024 (J Child Adolesc Psychopharmacol; May 2024), and O’Nions 2025 (Br J Psychiatry; Jan 2025). (gomez2023differencesbetweendsm5tr pages 3-4, thapar2023childhoodattentiondeficithyperactivity pages 1-2, pingault2023geneticnurtureversus pages 1-2, zhang2024attentiondeficithyperactivitydisordermedications pages 1-2, vasiliadis2024adhdmedicationsuse pages 1-2, nielsen2024sharedgeneticsof pages 2-3, wang2024amultiomicsstudy pages 1-2, huang2024clinicalstudyon pages 1-2, baweja2024fromconsensusstatement pages 1-2, onions2025lifeexpectancyand pages 1-2)

References

  1. (li2025theburdenof pages 1-2): Ningyu Li, Junqiang Zhao, and Fujun Zhou. The burden of attention deficit hyperactivity disorder and incidence rate forecast in china from 1990 to 2021. Frontiers in Psychiatry, Mar 2025. URL: https://doi.org/10.3389/fpsyt.2025.1532156, doi:10.3389/fpsyt.2025.1532156. This article has 10 citations.

  2. (li2025theburdenof pages 2-4): Ningyu Li, Junqiang Zhao, and Fujun Zhou. The burden of attention deficit hyperactivity disorder and incidence rate forecast in china from 1990 to 2021. Frontiers in Psychiatry, Mar 2025. URL: https://doi.org/10.3389/fpsyt.2025.1532156, doi:10.3389/fpsyt.2025.1532156. This article has 10 citations.

  3. (thapar2023childhoodattentiondeficithyperactivity pages 1-2): Ajay K. Thapar, Lucy Riglin, Rachel Blakey, Stephan Collishaw, George Davey Smith, Evie Stergiakouli, Kate Tilling, and Anita Thapar. Childhood attention-deficit hyperactivity disorder problems and mid-life cardiovascular risk: prospective population cohort study. The British Journal of Psychiatry, 223:472-477, Jul 2023. URL: https://doi.org/10.1192/bjp.2023.90, doi:10.1192/bjp.2023.90. This article has 18 citations.

  4. (pingault2023geneticnurtureversus pages 1-2): Jean-Baptiste Pingault, Wikus Barkhuizen, Biyao Wang, Laurie J. Hannigan, Espen Moen Eilertsen, Elizabeth Corfield, Ole A. Andreassen, Helga Ask, Martin Tesli, Ragna Bugge Askeland, George Davey Smith, Camilla Stoltenberg, Neil M. Davies, Ted Reichborn-Kjennerud, Eivind Ystrom, and Alexandra Havdahl. Genetic nurture versus genetic transmission of risk for adhd traits in the norwegian mother, father and child cohort study. Molecular Psychiatry, 28:1731-1738, Nov 2023. URL: https://doi.org/10.1038/s41380-022-01863-6, doi:10.1038/s41380-022-01863-6. This article has 66 citations and is from a highest quality peer-reviewed journal.

  5. (nielsen2024sharedgeneticsof pages 2-3): Trine Tollerup Nielsen, Jinjie Duan, Daniel F. Levey, G. Bragi Walters, Emma C. Johnson, Thorgeir Thorgeirsson, Daniel F. Levey, Joel Gelernter, Thomas Werge, Preben Bo Mortensen, Hreinn Stefansson, Kari Stefansson, David M. Hougaard, Arpana Agrawal, Joel Gelernter, Jakob Grove, Anders D. Børglum, and Ditte Demontis. Shared genetics of adhd, cannabis use disorder and cannabis use and prediction of cannabis use disorder in adhd. Nature Mental Health, 2:1071-1083, Jul 2024. URL: https://doi.org/10.1038/s44220-024-00277-3, doi:10.1038/s44220-024-00277-3. This article has 3 citations and is from a peer-reviewed journal.

  6. (nielsen2024sharedgeneticsof pages 1-2): Trine Tollerup Nielsen, Jinjie Duan, Daniel F. Levey, G. Bragi Walters, Emma C. Johnson, Thorgeir Thorgeirsson, Daniel F. Levey, Joel Gelernter, Thomas Werge, Preben Bo Mortensen, Hreinn Stefansson, Kari Stefansson, David M. Hougaard, Arpana Agrawal, Joel Gelernter, Jakob Grove, Anders D. Børglum, and Ditte Demontis. Shared genetics of adhd, cannabis use disorder and cannabis use and prediction of cannabis use disorder in adhd. Nature Mental Health, 2:1071-1083, Jul 2024. URL: https://doi.org/10.1038/s44220-024-00277-3, doi:10.1038/s44220-024-00277-3. This article has 3 citations and is from a peer-reviewed journal.

  7. (wang2024amultiomicsstudy pages 1-2): Jingkai Wang, Qiu-Wen Zhu, Jia-Hao Mai, Shun Zhang, Yuqing Wang, Jiatong Liang, and Ji-Yuan Zhou. A multi-omics study of brain tissue transcription and dna methylation revealing the genetic pathogenesis of adhd. Briefings in Bioinformatics, Sep 2024. URL: https://doi.org/10.1093/bib/bbae502, doi:10.1093/bib/bbae502. This article has 4 citations and is from a domain leading peer-reviewed journal.

  8. (gomez2023differencesbetweendsm5tr pages 3-4): Rapson Gomez, Wai Chen, and Stephen Houghton. Differences between dsm-5-tr and icd-11 revisions of attention deficit/hyperactivity disorder: a commentary on implications and opportunities. World Journal of Psychiatry, 13:138-143, May 2023. URL: https://doi.org/10.5498/wjp.v13.i5.138, doi:10.5498/wjp.v13.i5.138. This article has 58 citations.

  9. (gomez2023differencesbetweendsm5tr pages 5-7): Rapson Gomez, Wai Chen, and Stephen Houghton. Differences between dsm-5-tr and icd-11 revisions of attention deficit/hyperactivity disorder: a commentary on implications and opportunities. World Journal of Psychiatry, 13:138-143, May 2023. URL: https://doi.org/10.5498/wjp.v13.i5.138, doi:10.5498/wjp.v13.i5.138. This article has 58 citations.

  10. (vasiliadis2024adhdmedicationsuse pages 1-2): Helen-Maria Vasiliadis, Carlotta Lunghi, Elham Rahme, Louis Rochette, Martin Gignac, Victoria Massamba, Fatoumata Binta Diallo, Alvine Fansi, Samuele Cortese, and Alain Lesage. Adhd medications use and risk of mortality and unintentional injuries: a population-based cohort study. Translational Psychiatry, Feb 2024. URL: https://doi.org/10.1038/s41398-024-02825-y, doi:10.1038/s41398-024-02825-y. This article has 24 citations and is from a peer-reviewed journal.

  11. (zhang2024attentiondeficithyperactivitydisordermedications pages 1-2): Le Zhang, Lin Li, Pontus Andell, Miguel Garcia-Argibay, Patrick D. Quinn, Brian M. D’Onofrio, Isabell Brikell, Ralf Kuja-Halkola, Paul Lichtenstein, Kristina Johnell, Henrik Larsson, and Zheng Chang. Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry, 81:178, Feb 2024. URL: https://doi.org/10.1001/jamapsychiatry.2023.4294, doi:10.1001/jamapsychiatry.2023.4294. This article has 135 citations and is from a highest quality peer-reviewed journal.

  12. (zhang2024attentiondeficithyperactivitydisordermedications pages 6-7): Le Zhang, Lin Li, Pontus Andell, Miguel Garcia-Argibay, Patrick D. Quinn, Brian M. D’Onofrio, Isabell Brikell, Ralf Kuja-Halkola, Paul Lichtenstein, Kristina Johnell, Henrik Larsson, and Zheng Chang. Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry, 81:178, Feb 2024. URL: https://doi.org/10.1001/jamapsychiatry.2023.4294, doi:10.1001/jamapsychiatry.2023.4294. This article has 135 citations and is from a highest quality peer-reviewed journal.

  13. (onions2025lifeexpectancyand pages 1-2): Elizabeth O'Nions, Céline El Baou, Amber John, Dan Lewer, Will Mandy, Douglas G.J. McKechnie, Irene Petersen, and Josh Stott. Life expectancy and years of life lost for adults with diagnosed adhd in the uk: matched cohort study. The British Journal of Psychiatry, 226:261-268, Jan 2025. URL: https://doi.org/10.1192/bjp.2024.199, doi:10.1192/bjp.2024.199. This article has 56 citations.

  14. (baweja2024fromconsensusstatement pages 1-2): Raman Baweja, Stephen V. Faraone, Ann C. Childress, Margaret D. Weiss, Sandra K. Loo, Timothy E. Wilens, and James G. Waxmonsky. From consensus statement to pills to pixels: new innovations in attention-deficit/hyperactivity disorder care. Journal of Child and Adolescent Psychopharmacology, 34:167-182, May 2024. URL: https://doi.org/10.1089/cap.2024.0022, doi:10.1089/cap.2024.0022. This article has 15 citations and is from a peer-reviewed journal.

  15. (baweja2024fromconsensusstatement pages 10-11): Raman Baweja, Stephen V. Faraone, Ann C. Childress, Margaret D. Weiss, Sandra K. Loo, Timothy E. Wilens, and James G. Waxmonsky. From consensus statement to pills to pixels: new innovations in attention-deficit/hyperactivity disorder care. Journal of Child and Adolescent Psychopharmacology, 34:167-182, May 2024. URL: https://doi.org/10.1089/cap.2024.0022, doi:10.1089/cap.2024.0022. This article has 15 citations and is from a peer-reviewed journal.

  16. (baweja2024fromconsensusstatement pages 9-10): Raman Baweja, Stephen V. Faraone, Ann C. Childress, Margaret D. Weiss, Sandra K. Loo, Timothy E. Wilens, and James G. Waxmonsky. From consensus statement to pills to pixels: new innovations in attention-deficit/hyperactivity disorder care. Journal of Child and Adolescent Psychopharmacology, 34:167-182, May 2024. URL: https://doi.org/10.1089/cap.2024.0022, doi:10.1089/cap.2024.0022. This article has 15 citations and is from a peer-reviewed journal.

  17. (huang2024clinicalstudyon pages 1-2): Sheng Huang, Tianhui Zhang, Qing Lu, Xueqin Xiong, Zhisheng Liu, and Dan Sun. Clinical study on the intervention effect of digital therapy on children with attention deficit hyperactivity disorder (adhd). Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-73934-3, doi:10.1038/s41598-024-73934-3. This article has 13 citations and is from a peer-reviewed journal.

  18. (gomez2023differencesbetweendsm5tr pages 1-3): Rapson Gomez, Wai Chen, and Stephen Houghton. Differences between dsm-5-tr and icd-11 revisions of attention deficit/hyperactivity disorder: a commentary on implications and opportunities. World Journal of Psychiatry, 13:138-143, May 2023. URL: https://doi.org/10.5498/wjp.v13.i5.138, doi:10.5498/wjp.v13.i5.138. This article has 58 citations.

  19. (pingault2023geneticnurtureversus pages 4-5): Jean-Baptiste Pingault, Wikus Barkhuizen, Biyao Wang, Laurie J. Hannigan, Espen Moen Eilertsen, Elizabeth Corfield, Ole A. Andreassen, Helga Ask, Martin Tesli, Ragna Bugge Askeland, George Davey Smith, Camilla Stoltenberg, Neil M. Davies, Ted Reichborn-Kjennerud, Eivind Ystrom, and Alexandra Havdahl. Genetic nurture versus genetic transmission of risk for adhd traits in the norwegian mother, father and child cohort study. Molecular Psychiatry, 28:1731-1738, Nov 2023. URL: https://doi.org/10.1038/s41380-022-01863-6, doi:10.1038/s41380-022-01863-6. This article has 66 citations and is from a highest quality peer-reviewed journal.

  20. (gomez2023differencesbetweendsm5tr pages 4-5): Rapson Gomez, Wai Chen, and Stephen Houghton. Differences between dsm-5-tr and icd-11 revisions of attention deficit/hyperactivity disorder: a commentary on implications and opportunities. World Journal of Psychiatry, 13:138-143, May 2023. URL: https://doi.org/10.5498/wjp.v13.i5.138, doi:10.5498/wjp.v13.i5.138. This article has 58 citations.

  21. (cortese2025attention‐deficithyperactivitydisorder(adhd) pages 10-10): Samuele Cortese, Mark A. Bellgrove, Isabell Brikell, Barbara Franke, David W. Goodman, Catharina A. Hartman, Henrik Larsson, Frances R. Levin, Edoardo G. Ostinelli, Valeria Parlatini, Josep A. Ramos‐Quiroga, Margaret H. Sibley, Anneka Tomlinson, Timothy E. Wilens, Ian C.K. Wong, Nina Hovén, Jeremy Didier, Christoph U. Correll, Luis A. Rohde, and Stephen V. Faraone. Attention‐deficit/hyperactivity disorder (adhd) in adults: evidence base, uncertainties and controversies. World Psychiatry, 24:347-371, Sep 2025. URL: https://doi.org/10.1002/wps.21374, doi:10.1002/wps.21374. This article has 35 citations and is from a highest quality peer-reviewed journal.

  22. (cortese2025attention‐deficithyperactivitydisorder(adhd) pages 3-4): Samuele Cortese, Mark A. Bellgrove, Isabell Brikell, Barbara Franke, David W. Goodman, Catharina A. Hartman, Henrik Larsson, Frances R. Levin, Edoardo G. Ostinelli, Valeria Parlatini, Josep A. Ramos‐Quiroga, Margaret H. Sibley, Anneka Tomlinson, Timothy E. Wilens, Ian C.K. Wong, Nina Hovén, Jeremy Didier, Christoph U. Correll, Luis A. Rohde, and Stephen V. Faraone. Attention‐deficit/hyperactivity disorder (adhd) in adults: evidence base, uncertainties and controversies. World Psychiatry, 24:347-371, Sep 2025. URL: https://doi.org/10.1002/wps.21374, doi:10.1002/wps.21374. This article has 35 citations and is from a highest quality peer-reviewed journal.

  23. (baweja2024fromconsensusstatement media baf871c0): Raman Baweja, Stephen V. Faraone, Ann C. Childress, Margaret D. Weiss, Sandra K. Loo, Timothy E. Wilens, and James G. Waxmonsky. From consensus statement to pills to pixels: new innovations in attention-deficit/hyperactivity disorder care. Journal of Child and Adolescent Psychopharmacology, 34:167-182, May 2024. URL: https://doi.org/10.1089/cap.2024.0022, doi:10.1089/cap.2024.0022. This article has 15 citations and is from a peer-reviewed journal.

OpenScientist ▸
1. Disease Information
openscientist-autonomous 60 citations 2026-05-05T08:04:34.118108

1. Disease Information

Overview

ADHD is a childhood-onset neurodevelopmental disorder defined by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity that persist for at least six months and cause clinically significant impairment in social, academic, or occupational functioning. It is classified as a psychiatric/behavioral disorder and recognized across all major diagnostic systems.

Key Identifiers

Database Identifier
MONDO MONDO:0007743
OMIM 143465
ICD-10 F90 (Hyperkinetic disorders); F90.0 (Disturbance of activity and attention)
ICD-11 6A05 (Attention deficit hyperactivity disorder)
MeSH D001289 (Attention Deficit Disorder with Hyperactivity)
DSM-5 314.00 (Predominantly inattentive); 314.01 (Predominantly hyperactive-impulsive / Combined)
SNOMED CT 406506008

Synonyms and Alternative Names

  • Attention Deficit Disorder (ADD)
  • Attention Deficit Disorder with Hyperactivity
  • Hyperkinetic Disorder (ICD terminology)
  • Hyperkinetic Syndrome
  • Minimal Brain Dysfunction (historical)
  • ADHD-Inattentive type (ADHD-I)
  • ADHD-Hyperactive/Impulsive type (ADHD-HI)
  • ADHD-Combined type (ADHD-C)

Information Sources

This report is derived from aggregated disease-level resources including systematic reviews, meta-analyses, genome-wide association studies, international consensus statements, and landmark clinical reviews. Key sources include the World Federation of ADHD International Consensus Statement (PMID: 33549739), authoritative Lancet reviews (PMID: 26386541), and large-scale GWAS meta-analyses (PMID: 30478444).

2. Etiology

Disease Causal Factors

ADHD is a multifactorial disorder with contributions from genetic, environmental, and gene-environment interaction factors. As stated in the Lancet review: "ADHD is highly heritable and multifactorial; multiple genes and non-inherited factors contribute to the disorder" (PMID: 26386541). No single causal agent has been identified; rather, multiple genes of small individual effect combine with environmental exposures to create a spectrum of neurobiological liability.

Genetic Risk Factors

Heritability: The mean heritability of ADHD is 0.74-0.77 from twin studies, comparable to schizophrenia and bipolar disorder (PMID: 17718779). Family studies identify a 2- to 8-fold increase in risk for ADHD in parents and siblings of affected children.

GWAS Findings: The landmark GWAS meta-analysis by Demontis et al. (2019) of 20,183 ADHD cases and 35,191 controls identified "variants surpassing genome-wide significance in 12 independent loci" (PMID: 30478444). These associations were enriched in evolutionarily constrained genomic regions and loss-of-function intolerant genes. A subsequent GWAS expanded this to 27 genome-wide significant loci (PMID: 39510315).

Candidate Genes: Meta-analyses of candidate gene studies have identified "significant associations... including DAT1, DRD4, DRD5, 5HTT, HTR1B, and SNAP25" (PMID: 19506906).

Gene Protein Pathway Evidence
SLC6A3 (DAT1) Dopamine transporter Dopaminergic GWAS + candidate gene meta-analyses
DRD4 Dopamine receptor D4 Dopaminergic Candidate gene meta-analyses
DRD5 Dopamine receptor D5 Dopaminergic Candidate gene meta-analyses
SLC6A4 (5HTT) Serotonin transporter Serotonergic Candidate gene meta-analyses
HTR1B Serotonin receptor 1B Serotonergic Candidate gene meta-analyses
SNAP25 Synaptosomal-associated protein 25 Synaptic vesicle Candidate gene + GWAS
BAIAP2 Brain-specific angiogenesis inhibitor 1-associated protein 2 Synaptic signaling Adult ADHD meta-analysis (PMID: 27217152)
ADGRL3 (LPHN3) Latrophilin 3 Cell adhesion/signaling Pharmacogenetic studies (PMID: 28871191)

Rare Variants: Likely pathogenic rare variants were identified in 13% of pediatric ADHD cases versus 0.5% of controls. ADHD cases without rare variants had higher polygenic scores than those carrying rare variants, suggesting "independent contributions from common and rare variants" (PMID: 41076565).

Environmental Risk Factors

Risk Factor Evidence Level Key References
Maternal smoking during pregnancy Strong PMID: 17718779
Prenatal alcohol exposure Strong PMID: 17718779
Low birth weight/prematurity Strong PMID: 33549739
Lead contamination Moderate-Strong PMID: 17718779
Food additives/diet Moderate PMID: 17718779
Polychlorinated biphenyls (PCBs) Moderate PMID: 34848247
Psychosocial adversity Moderate PMID: 33549739
Endocrine disrupting chemicals (phthalates, BPA) Emerging PMID: 42027687

Protective Factors

  • Breastfeeding: Associated with reduced ADHD risk in several epidemiological studies
  • Omega-3 fatty acid intake: Lower serum docosahexaenoic acid (DHA) levels found in ADHD adults; supplementation may be protective (PMID: 27217152)
  • Physical exercise: Demonstrates highest effect size among non-pharmacological interventions (Morris d = 0.93) for cognitive difficulties (PMID: 31629998)
  • Healthy gut microbiome: Emerging evidence suggests balanced microbiota may be neuroprotective (PMID: 42027687)

Gene-Environment Interactions

Environmental ADHD risk factors including toxic, nutritional factors, and stressful life events lead to changes in DNA methylation and histone modification levels (PMID: 28665177). The amygdala serotonin transporter gene network interacts with postnatal adversity to predict attention and hyperactivity problems, with both postnatal adversity and ePRS-5-HTT scores associated with variation in DNA methylation across the genome (PMID: 32256307). The gut-brain axis has emerged as a mediating pathway through which endocrine-disrupting chemicals may influence ADHD risk via gut microbiota dysbiosis, immune activation, and neuroinflammatory cascades (PMID: 42027687).

3. Phenotypes

Core Symptom Domains

Inattention (HP:0007018 - Attention deficit)

  • Type: Behavioral change
  • Onset: Childhood (typically before age 12); may persist into adulthood
  • Severity: Variable (mild to severe)
  • Progression: Relatively stable across age groups; does not decline significantly with age
  • Frequency: Present in virtually all ADHD subtypes (~100% in ADHD-I and ADHD-C)
  • QoL Impact: Significant impairment in academic achievement, occupational performance, and daily organization
  • DSM-5 Examples: Difficulty sustaining attention, not listening when spoken to, failing to follow through on tasks, losing things, easily distracted, forgetful

Hyperactivity (HP:0000752 - Hyperactivity)

  • Type: Behavioral/physical manifestation
  • Onset: Childhood, often earlier than inattention (preschool years)
  • Severity: Variable; often decreases with age
  • Progression: Tends to decline from childhood through adolescence and adulthood; may manifest as inner restlessness in adults
  • Frequency: Present in ADHD-HI and ADHD-C subtypes (~60-70% of ADHD cases)
  • QoL Impact: Disrupts classroom behavior, social interactions, occupational settings
  • DSM-5 Examples: Fidgeting, leaving seat, running/climbing inappropriately, unable to play quietly, "on the go," excessive talking

Impulsivity (HP:0100710 - Impulsivity)

  • Type: Behavioral change
  • Onset: Childhood; often co-presents with hyperactivity
  • Severity: Variable
  • Progression: May decrease with age but can persist as risk-taking behavior in adults
  • Frequency: Present in ADHD-HI and ADHD-C subtypes
  • QoL Impact: Increased risk of accidents (OR = 2.2 for multiple collisions, PMID: 25843156), substance use, legal problems, social difficulties

Associated Phenotypes

Phenotype HPO Term Frequency Notes
Executive dysfunction HP:0001328 ~80-90% Working memory, planning, cognitive flexibility deficits
Emotional dysregulation HP:0100851 ~70% Emotional lability, low frustration tolerance
Sleep disturbances HP:0002360 ~25-50% Difficulty falling/staying asleep
Object recognition memory deficits — Variable Cohen's d ~ 0.49 vs. controls (PMID: 38907905)
Disorganization — Very frequent Absent from DSM-5 triad but identified in adult studies
Time perception difficulties — Frequent Identified in qualitative adult ADHD research (PMID: 41640011)
Obesity/overweight HP:0001513 14.7% obesity, 20.9% overweight Meta-analysis (PMID: 32783349)

Quality of Life Impact

Children treated for ADHD show significantly worse outcomes across multiple domains: higher rates of unauthorized school absence (adjusted IRR 1.16), exclusion (adjusted IRR 5.79), special educational need (adjusted OR 8.62), lower academic attainment (adjusted OR 3.35), earlier school leaving (64.3% vs 28.4% before age 16), higher unemployment (adjusted OR 1.39), and more hospitalizations (adjusted HR 1.25), including for injury (adjusted HR 1.52) (PMID: 28459927).

4. Genetic/Molecular Information

Causal Genes and Pathogenic Variants

ADHD does not follow classical Mendelian inheritance with single causal genes. Instead, it has a polygenic architecture with multiple common variants of small effect and rare variants of larger effect.

GWAS-identified loci (12 genome-wide significant from Demontis et al.): Include regions near genes involved in neurodevelopmental processes. Associations were "enriched in evolutionarily constrained genomic regions and loss-of-function intolerant genes" (PMID: 30478444).

TWAS-identified genes from integration of prenatal brain expression data with GWAS: LSM6, HYAL3, METTL15, RPS26, LRRC37A15P, RP11-142I20.1, ABCB9, AP006621.5, AC000068.5, and PDXDC1 (PMID: 39510315).

Multivariate GWAS identified shared genetic architecture between ADHD and related psychiatric disorders, with protein tyrosine phosphatase receptor type D (PTPRD) emerging as a promising candidate, and cell typing implicating the cerebellum and cholinergic neurons (PMID: 41729977).

Variant Classification

For common variants: These are classified as susceptibility loci rather than pathogenic variants in the ACMG/AMP framework. Individual SNPs have small effect sizes (OR typically 1.1-1.3). Polygenic risk scores combining multiple variants can predict ADHD with ~70% AUC when combined with IQ polygenic scores, ancestry, and rare variant status (PMID: 41076565).

For rare variants: 13% of pediatric ADHD cases carry likely pathogenic rare variants (vs. 0.5% controls), classified per ACMG guidelines.

Modifier Genes

  • COMT (catechol-O-methyltransferase): Val158Met polymorphism modifies prefrontal dopamine availability
  • MAOA (monoamine oxidase A): Modifies catecholamine metabolism
  • BDNF (brain-derived neurotrophic factor): Modifies neurodevelopmental processes
  • SLC6A2 (norepinephrine transporter): Intronic rs3785143 associated with inattention symptoms (PMID: 29374517)

Epigenetic Information

  • A critical CpG site in the DRD4 gene promoter exhibits a specific methylation pattern in ADHD children (PMID: 28665177)
  • The amygdala 5-HTT gene network interacts with postnatal adversity to predict attention problems, and this interaction associates with genome-wide DNA methylation variation and brain gray matter density (PMID: 32256307)
  • Environmental risk factors (toxins, nutritional factors, stressful life events) lead to changes in both DNA methylation and histone modification levels

Chromosomal Abnormalities

  • 2q13 deletions/duplications: Associated with high rates of ADHD (48% deletion carriers, 60% duplication carriers) (PMID: 29603867)
  • 15q11.2 BP1-BP2 CNVs: Associated with ADHD among other neurodevelopmental disorders (PMID: 37129092)
  • 22q11.2 microdeletions (DiGeorge/velocardiofacial syndrome): Increased risk of ADHD among other neuropsychiatric conditions (PMID: 28259864)
  • Large, rare CNVs are not enriched in ADHD to the same degree as in schizophrenia (PMID: 24127788)

5. Environmental Information

Environmental Factors

Factor Category Evidence CHEBI/Ontology
Lead (Pb) Heavy metal Strong association; neurotoxic CHEBI:25016
Polychlorinated biphenyls (PCBs) Persistent organic pollutant Moderate association CHEBI:53156
Phthalates Endocrine disruptor Emerging epidemiological evidence CHEBI:64200
Bisphenol A (BPA) Endocrine disruptor Emerging evidence via gut-brain axis CHEBI:33216
Pesticides (organophosphates) Agricultural chemical Moderate association —
Food additives/artificial colors Dietary chemical Moderate (variable findings) —

The gut-brain axis has been proposed as a mediating pathway linking environmental endocrine-disrupting chemicals to ADHD through gut microbiota dysbiosis, immune activation, and neuroinflammatory processes (PMID: 42027687).

Lifestyle Factors

  • Maternal smoking during pregnancy: One of the most consistently replicated environmental risk factors
  • Prenatal alcohol exposure: Associated with ADHD symptoms; a validated rodent model uses prenatal alcohol exposure (PMID: 35367465)
  • Diet: Omega-3 fatty acid deficiency (lower DHA levels in ADHD adults); elimination diets show modest effects in some children
  • Screen time/technology use: Associated with ADHD-like symptoms, though direction of causality remains debated (PMID: 41520374)
  • Sleep quality: Poor sleep associated with ADHD symptoms and may exacerbate functional impairment

Infectious Agents

  • Streptococcal infections: PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections) may present with ADHD-like symptoms
  • Gut microbiota dysbiosis: ADHD-associated microbial signature includes reduced alpha diversity, elevated Firmicutes/Bacteroidetes ratio, and altered Bifidobacterium populations (PMID: 40442917; PMID: 42027687)

6. Mechanism / Pathophysiology

Molecular Pathways

The catecholamine deficit hypothesis is the predominant pathophysiological framework: "Stimulants, a principle treatment for the disorder, act on the norepinephrine (NE) and dopamine (DA) systems; this has led to a long-standing hypothesis of catecholamine dysfunction in ADHD" (PMID: 15950012). The monoamine deficit hypothesis postulates "a dysbalance in the interaction of the neurotransmitters dopamine, noradrenaline and serotonin" (PMID: 24446115).

Key pathways involved: - Dopaminergic signaling (GO:0007212): Reduced dopamine release in prefrontal cortex, striatum - Noradrenergic signaling (GO:0007210): Impaired autoreceptor-mediated regulation in prefrontal cortex - Serotonergic signaling (GO:0007210): Modulatory role in impulsivity and emotional regulation - GABAergic neurotransmission: Enrichment in prenatal GABAergic neurons (PMID: 37464041) - Glutamatergic signaling: Glutamate receptor genes identified as risk loci

Causal Chain: Initial Trigger to Clinical Manifestation

GENETIC SUSCEPTIBILITY          ENVIRONMENTAL EXPOSURES
(Polygenic risk + rare variants)    (Prenatal toxins, adversity)
    |                              |
    +-------------+---------------+
          |
          v
    EPIGENETIC MODIFICATIONS
      (DNA methylation, histone changes)
          |
          v
ALTERED GENE EXPRESSION IN
DEVELOPING BRAIN (prenatal)
     (LSM6, RPS26, catecholamine genes)
          |
          v
       CATECHOLAMINE SYSTEM DYSREGULATION
    +-------------+------------------+
    |             |                  |
    v             v                  v
 Low DA in    High NE in      Low DA in
 PFC          PFC             striatum
    |             |                  |
    v             v                  v
 FRONTO-STRIATAL-CEREBELLAR CIRCUIT DYSFUNCTION
    |             |                  |
    v             v                  v
INATTENTION    HYPERACTIVITY     IMPULSIVITY
(Executive     (Motor excess)    (Response
 dysfunction)                     inhibition
                  failure)

Cellular Processes

  • Synaptic transmission (GO:0007268): Disrupted dopamine and norepinephrine neurotransmission at synapses
  • Neuron development (GO:0048666): TWAS-identified risk genes (LSM6, RPS26) show high expression during early brain development (PMID: 40739630)
  • Neuroinflammation: Emerging evidence for pro-inflammatory cytokine involvement (IL-6, TNF-alpha) and microglial activation (PMID: 38026703)
  • Neuronal migration and circuit formation: Genetic variants may contribute to ADHD by "modulating gene expression in the fetal brain, thereby impacting early neurodevelopmental processes" (PMID: 40739630)

Protein Dysfunction

  • Dopamine transporter (DAT/SLC6A3): Altered dopamine reuptake kinetics; impaired vesicular storage in SHR model causing dopamine leakage into cytoplasm (PMID: 11864734)
  • Dopamine receptors (DRD4, DRD5): Altered receptor sensitivity/density affecting postsynaptic signaling
  • SNAP-25: Disrupted SNARE complex function affecting synaptic vesicle fusion and neurotransmitter release

Metabolic Changes

  • Lower DHA (docosahexaenoic acid) levels in ADHD adults (significant after Bonferroni correction; PMID: 27217152)
  • Altered tryptophan metabolism via gut-brain axis pathways (PMID: 42027687)
  • Elevated GFAP and GAD65 antibody levels in children with ADHD, correlating with symptom severity (PMID: 41864973)

Immune System Involvement

  • Peripheral inflammatory markers and stress contribute to ADHD pathophysiology; neural circuits regulating emotions appear "particularly vulnerable to inflammatory insults and peripheral inflammation" (PMID: 38026703)
  • Gut microbiota-mediated immune pathway enrichment in enteric inflammation and CNS processes (PMID: 42027687)

Cell Types Involved

Cell Type CL Term Role
Dopaminergic neuron CL:0000700 Primary pathophysiological cell type
Noradrenergic neuron CL:0000214 Prefrontal cortex regulation
Excitatory glutamatergic neuron CL:0000679 SNP-based heritability enrichment (PMID: 40739630)
Cholinergic neuron CL:0000108 Cell typing enrichment (PMID: 41729977)
GABAergic neuron CL:0000617 Prenatal enrichment (PMID: 37464041)
Astrocyte CL:0000127 Enrichment in depression/ADHD GWAS (PMID: 37464041)
Medium spiny neuron CL:1001474 Striatal dysfunction

Molecular Profiling

Transcriptomics: Risk genes from integrative TWAS analyses show high expression during early brain development, with excitatory glutamatergic neuron enrichment for ADHD heritability (PMID: 40739630).

Metabolomics: Lower serum DHA levels in ADHD adults; altered polyunsaturated fatty acid profiles (PMID: 27217152). Elevated plasma GFAP and GAD65-Ab levels correlate with ADHD symptom severity in children (PMID: 41864973).

Epigenomics: DNA methylation changes in DRD4 promoter and genome-wide methylation variation associated with serotonin transporter gene network activity (PMID: 28665177; PMID: 32256307).

7. Anatomical Structures Affected

Organ Level

Primary: Central nervous system (brain) — UBERON:0000955

Body systems involved: Nervous system (primary), endocrine system (HPA axis), gastrointestinal system (gut-brain axis)

Brain Regions

Region UBERON Term Evidence Role
Prefrontal cortex UBERON:0000451 fMRI, structural MRI, lesion studies Executive function, attention
Dorsolateral prefrontal cortex UBERON:0009834 Hypoactivation in ADHD Working memory, planning
Anterior cingulate cortex UBERON:0009835 Hyperactivation to reward Error monitoring, conflict
Basal ganglia (striatum) UBERON:0002038 Structural/functional changes Motor control, reward
Caudate nucleus UBERON:0001873 Altered functional connectivity (PMID: 28863310) Response selection
Cerebellum UBERON:0002037 Volumetric reductions, especially vermis Timing, motor coordination
Cerebellar vermis (lobules VIII-X) — Smaller volumes in ADHD (PMID: 16451810) Posterior-inferior vermis
Amygdala UBERON:0001876 Altered activation to emotional stimuli Emotional processing
Orbitofrontal cortex UBERON:0004167 Reward processing abnormalities Reward valuation

Neural Network Level

Meta-analysis of 55 fMRI studies reveals: "In children, hypoactivation in ADHD relative to comparison subjects was observed mostly in systems involved in executive function (frontoparietal network) and attention (ventral attentional network). Significant hyperactivation in ADHD relative to comparison subjects was observed predominantly in the default, ventral attention, and somatomotor networks" (PMID: 22983386).

Subcellular Level

Compartment GO Cellular Component Role in ADHD
Synaptic vesicle GO:0008021 Dopamine storage/release (impaired in SHR model)
Synaptic cleft GO:0043083 Altered neurotransmitter concentrations
Presynaptic membrane GO:0042734 DAT-mediated dopamine reuptake
Postsynaptic density GO:0014069 Receptor signaling (DRD4, DRD5)

Lateralization

Predominantly bilateral but with some asymmetric findings. The right hemisphere (particularly right inferior frontal gyrus) is consistently implicated in response inhibition deficits. Some studies show left-lateralized prefrontal abnormalities (PMID: 41131279).

8. Temporal Development

Onset

  • Typical age of onset: Childhood (DSM-5 requires several symptoms present before age 12)
  • Onset pattern: Insidious/chronic; symptoms develop gradually during early childhood
  • Earliest manifestations: Hyperactivity may appear in preschool (ages 3-5); inattention typically becomes apparent in school-age years (ages 6-12)
  • Adult-onset: Growing recognition that some individuals may not be diagnosed until adulthood; prevalence of 14.6% of U.S. adults meeting DSM-5 criteria (PMID: 39172673)

Progression

  • Disease course: Chronic, lifelong in many cases
  • Symptom trajectory: Hyperactivity-impulsivity (HI) scores decline with age; inattention (IA) scores remain relatively stable (PMID: 41716858)
  • Persistence: Approximately 50-65% of children with ADHD continue to meet full criteria in adulthood
  • Remission: Some individuals achieve remission. Normalization of prefrontal cortical activity drives remission, while subcortical (caudate) anomalies reflect childhood ADHD history and persist even in remission (PMID: 28659040)

Critical Periods

  • Prenatal period: Window of vulnerability for environmental exposures (smoking, alcohol, toxins)
  • Early childhood (ages 3-6): Critical window for behavioral manifestation and early identification
  • School entry (ages 6-8): Peak period for diagnosis when academic demands increase
  • Adolescence: Period of changing symptom profiles; transition from hyperactivity to internal restlessness
  • Young adulthood: Critical period for functional outcomes (education completion, employment entry)

9. Inheritance and Population

Epidemiology

Prevalence: - Children (<=18 years): Worldwide-pooled prevalence of 5.29% from meta-analysis of 102 studies with 171,756 subjects. "The ADHD/HD worldwide-pooled prevalence was 5.29%. This estimate was associated with significant variability" (PMID: 17541055) - Adults: Approximately 2.5% (PMID: 26386541) - Stability over time: "Geographical location and year of study were not associated with variability in ADHD prevalence estimates" (PMID: 24464188)

Inheritance Pattern

  • Multifactorial/polygenic — not Mendelian
  • Heritability: Mean h-squared = 0.74-0.77 (twin studies)
  • Penetrance: Incomplete; polygenic risk is probabilistic
  • Expressivity: Highly variable; ranging from mild inattention to severe combined presentation
  • No genetic anticipation, founder effects, or consanguinity role in typical ADHD

Population Demographics

Sex ratio: - Male:Female in children: Approximately 2-3:1 (clinical samples); closer to 1.5:1 in community samples - "It is more common in boys than girls" (PMID: 26386541) - Females may be underdiagnosed due to higher rates of inattentive (rather than hyperactive) presentation - In adults, the sex ratio narrows; medication use patterns show faster increases among females (PMID: 41156208)

Geographic distribution: Present in all world regions studied; prevalence differences largely explained by methodological rather than geographic factors (PMID: 24464188)

Age distribution: Peak diagnosis in school-age children (6-12 years); increasing recognition in adults and preschoolers

10. Diagnostics

Clinical Criteria

DSM-5 (Standardized diagnostic criteria): - 6+ symptoms of inattention and/or 6+ symptoms of hyperactivity-impulsivity (5+ for adults >=17 years) - Symptoms present before age 12 - Symptoms present in two or more settings - Clear evidence of clinically significant impairment - Three presentations: Predominantly Inattentive, Predominantly Hyperactive-Impulsive, Combined

ICD-11: Attention deficit hyperactivity disorder (6A05) with similar criteria structure

Assessment Tools: - Adult ADHD Self-Report Scale (ASRS) - Conners Adult ADHD Rating Scales (CAARS) - ADHD Rating Scale-5 (ADHD-RS-5) (PMID: 41716858) - Wender-Utah Rating Scale (retrospective childhood symptoms) - Clinical interview remains the gold standard

Biomarkers (Research Stage)

Biomarker Type Evidence
EEG theta/beta ratio Electrophysiology Elevated frontal theta power, higher theta/beta ratio in ADHD-I (PMID: 41207280)
P300 wave features Electrophysiology Prolonged latency, reduced amplitude in ADHD-I
Serum BDNF, NGF, GDNF, NTF3 Circulating proteins NGF and NTF3 elevated in ADHD-HI; combined EEG + serum markers yield AUC 0.90 for ADHD-I vs ADHD-HI differentiation
Plasma GFAP Circulating protein Correlates with hyperactivity-impulsivity ratings (PMID: 41864973)
GAD65 antibodies Autoantibody Elevated in ADHD children
Serum DHA levels Metabolite Lower in ADHD adults (PMID: 27217152)

Imaging Studies

  • Structural MRI: Subtle global cerebral volume reductions in adults; smaller cerebellar vermis volumes in children (PMID: 26115789; PMID: 16451810)
  • fMRI: Hypoactivation in frontoparietal and ventral attentional networks; hyperactivation in default mode network (PMID: 22983386)
  • Note: Neuroimaging is currently a research tool, not a clinical diagnostic tool

Genetic Testing

Genetic testing is not routinely recommended for ADHD diagnosis. However: - Chromosomal microarray: May be indicated when ADHD co-occurs with intellectual disability or dysmorphic features - WES/WGS: Research tool; can identify rare pathogenic variants in ~13% of cases - Polygenic risk scores: Research stage; combined with rare variant status achieves 70% AUC (PMID: 41076565)

Differential Diagnosis

Anxiety disorders, mood disorders (depression, bipolar disorder), autism spectrum disorder, learning disabilities, oppositional defiant disorder, conduct disorder, substance use disorders, thyroid disorders, sleep disorders, and trauma/PTSD should be considered. There is substantial symptom overlap and high comorbidity rates.

11. Outcome/Prognosis

Mortality and Morbidity

  • ADHD is associated with heightened risk of premature mortality, primarily through accidents and injuries
  • Individuals with ADHD have significantly higher risk of multiple motor vehicle collisions (OR = 2.2) and collision fault (OR = 2.1) (PMID: 25843156)
  • Childhood ADHD is associated with 4.74-fold increased risk of subsequent psychotic disorder (pooled relative effect from meta-analysis of 1.85 million participants; PMID: 33625499)

Functional Outcomes

Even while receiving medication, children with ADHD fare significantly worse across education and health outcomes (PMID: 28459927). ADHD is associated with higher rates of: - Psychiatric comorbidity (anxiety, depression, substance use disorders, personality disorders) - Academic underachievement and school dropout - Unemployment and underemployment - Relationship difficulties and divorce - Increased healthcare utilization

Prognostic Factors

  • Favorable: Higher IQ, absence of comorbid conditions, supportive family environment, early treatment, persistence with medication
  • Unfavorable: Comorbid conduct disorder, substance use, low socioeconomic status, high polygenic burden, poor treatment adherence
  • ADHD medication use is associated with better adherence to treatment for comorbid conditions (e.g., antihypertensives: OR 0.66 for poor adherence; PMID: 41721349)

12. Treatment

Pharmacotherapy

Stimulants (First-Line) — MAXO:0000016 (pharmacotherapy)

Medication Class Mechanism Effect Size (QoL)
Methylphenidate Stimulant DAT + NET blockade Hedge's g = 0.38 vs. placebo
Amphetamines (d-AMP, lisdexamfetamine) Stimulant DA/NE release + reuptake inhibition Hedge's g = 0.51 vs. placebo

"Amphetamines (Hedge's g = 0.51, 95% CI = 0.08, 0.94), methylphenidate (0.38; 0.23, 0.54), and atomoxetine (0.30; 0.19, 0.40) were significantly more efficacious than placebo in improving QoL in people with ADHD" (PMID: 38823477).

Methylphenidate is the most widely prescribed medication globally. It blocks dopamine and norepinephrine transporters with relatively large effect sizes in short-term trials (PMID: 34174276). Methylphenidate remained the most prescribed drug, although lisdexamfetamine and guanfacine use has expanded in recent years (PMID: 41156208).

Non-Stimulants (Second-Line)

Medication Mechanism Evidence
Atomoxetine Selective NE reuptake inhibitor Hedge's g = -0.48 for ADHD symptoms in adults (PMID: 37166701)
Guanfacine Alpha-2A adrenergic agonist Hedge's g = -0.66 in adults; lower acceptability
Clonidine Alpha-2 adrenergic agonist FDA-approved for ADHD; used especially with tic comorbidity
Viloxazine ER NE reuptake inhibitor/5-HT modulator FDA-approved 2021; effective vs. placebo
Bupropion DA/NE reuptake inhibitor Evidence for efficacy; off-label use

Pharmacogenomics

  • CYP2D6 phenotype: Affects atomoxetine metabolism; CYP2D6 poor metabolizers have higher plasma levels (PMID: 36645468)
  • SLC6A3 VNTR: Meta-analysis shows this is "not a reliable predictor of methylphenidate treatment success" overall, though naturalistic trials suggest 10R homozygotes show less improvement (PMID: 23588108)
  • NET (SLC6A2) promoter rs28386840: T-allele carriers show better hyperactivity-impulsivity improvement with methylphenidate (PMID: 29374517)
  • SLC6A3 rs2550948, DRD4 promoter duplication, SNAP25 rs3746544, ADGRL3 rs1868790: Associated with 12-month MPH response (PMID: 28871191)

Non-Pharmacological Interventions — MAXO:0000950 (psychotherapy)

Intervention Effect Size Maintenance
Physical exercise Morris d = 0.93 (highest for cognitive difficulties) Poor long-term maintenance
Cognitive training Significant improvement Good maintenance
Behavior therapy Significant improvement Best sustained effect (SUCRA: 95.1%)
Neurofeedback Significant improvement Diminishing over time
Cognitive behavioral therapy SMD -0.76 (clinician-rated) —
Mindfulness meditation Improved awareness; decreased hyperactivity/inattention (PMID: 32163834) —

"Physical exercises demonstrated the highest average effect size (Morris d = 0.93)" for cognitive difficulties in ADHD (PMID: 31629998).

Network meta-analysis of long-term non-pharmacological treatments found that behavior therapy demonstrated the best sustained effect (SUCRA: 95.1%), while physical exercise showed the best immediate effect but poor maintenance (PMID: 40398202).

Treatment Strategy

Current clinical guidelines recommend an individualized multimodal treatment approach including psychoeducation, pharmacological interventions, and non-pharmacological interventions (PMID: 34174276). Stimulant optimization should be prioritized before switching to alternative pharmacological strategies (PMID: 34403134).

13. Prevention

Primary Prevention

  • Reducing prenatal exposures: Smoking cessation programs for pregnant women; minimizing alcohol, lead, and environmental toxin exposure
  • Optimizing prenatal nutrition: Ensuring adequate omega-3 fatty acid (DHA) intake during pregnancy
  • Minimizing endocrine disruptor exposure: Reducing phthalate and BPA exposure during pregnancy and early childhood

Secondary Prevention (Early Detection)

  • Universal developmental screening in pediatric primary care
  • Teacher and parent rating scales at school entry (ages 5-6)
  • Genetic risk stratification: Polygenic risk scores may eventually identify high-risk children for targeted early intervention (research stage)
  • Microbiome monitoring: Emerging evidence suggests infant gut microbiome composition may predict neurodevelopmental outcomes (PMID: 33271210)

Tertiary Prevention

  • Medication adherence support: ADHD itself impairs treatment adherence; structured monitoring programs are essential
  • Comorbidity screening and treatment: Systematic screening for anxiety, depression, substance use, and learning disabilities
  • Psychoeducation: For patients, families, and educators
  • Driving safety interventions: Given significantly elevated accident risk (OR = 2.2 for multiple collisions)
  • Academic and occupational accommodations

Behavioral Interventions

  • Physical exercise programs (highest immediate effect sizes for cognitive improvement)
  • Behavioral parent training
  • Classroom management strategies
  • Social skills training
  • Organizational skills training
  • Mindfulness-based interventions

14. Other Species / Natural Disease

Naturally Occurring Models

ADHD-like behaviors have been observed in several animal species:

  • Domestic dogs: Hyperactivity, impulsivity, and inattention behaviors recognized in veterinary behavioral medicine
  • Horses: Attention and impulsivity variations noted

Orthologous Genes

Human Gene Mouse Ortholog NCBI Gene ID (Mouse) ADHD Relevance
SLC6A3 (DAT1) Slc6a3 13162 Dopamine transporter; KO mice hyperactive
DRD4 Drd4 13491 Dopamine receptor D4
SNAP25 Snap25 20614 Coloboma mouse (haploinsufficiency)
ADGRL3 (LPHN3) Adgrl3 319387 Latrophilin 3; KO rats show ADHD-like behavior
SLC6A2 (NET) Slc6a2 20538 Norepinephrine transporter

Comparative Biology

The consistency of findings regarding dopaminergic, noradrenergic, and serotonergic system involvement across species supports evolutionary conservation of the catecholaminergic circuits disrupted in ADHD. The spontaneously hypertensive rat (SHR) model demonstrates "hypodopaminergic and hypernoradrenergic activity in prefrontal cortex" — consistent with the human catecholamine imbalance hypothesis (PMID: 11864734).

15. Model Organisms

Genetic Models

Model Species Construct Validity Face Validity Predictive Validity
Spontaneously Hypertensive Rat (SHR) Rat Polygenic; catecholamine dysregulation Hyperactivity, impulsivity, inattention Responds to stimulants
DAT knockout mouse Mouse SLC6A3 loss of function Extreme hyperactivity Paradoxical calming by stimulants
Coloboma mouse (SNAP-25) Mouse SNAP25 haploinsufficiency Hyperactivity Partial stimulant response
LPHN3/ADGRL3 knockout Rat/Mouse ADGRL3 loss of function ADHD-like behaviors High construct validity
NK1 receptor knockout Mouse Tachykinin-1 receptor KO Hyperactivity, inattention —

Environmentally Induced Models

Model Intervention Relevance
Prenatal nicotine exposure Nicotine during gestation Models maternal smoking risk factor
Prenatal alcohol exposure Ethanol during gestation Models fetal alcohol-related ADHD
Neonatal 6-OHDA lesion Dopamine neuron lesion Models dopaminergic deficiency
Lead exposure Developmental Pb exposure Models environmental toxin risk

Model Characteristics and Limitations

The SHR (Charles River Laboratories substrain) has the most translational support and "the most translational support at this stage to model ADHD/SUD comorbidity" (PMID: 35367465). The SHR displays "hyperactivity, impulsivity, poor stability of performance, impaired ability to withhold responses and poorly sustained attention" compared with Wistar-Kyoto controls (PMID: 11864734).

Key insight from animal models: "The major insight provided by animal models was the consistency of findings regarding the involvement of dopaminergic, noradrenergic, and sometimes also serotonergic systems, as well as more fundamental defects in neurotransmission" (PMID: 21207367).

Limitations: No single animal model captures all aspects of ADHD. Models cannot fully recapitulate the cognitive complexity (executive function, metacognition) of human ADHD. The subjective experience of inattention and emotional dysregulation is not directly measurable in animals. Current models do not adequately address the polygenic nature of the disorder, and gene-environment interactions remain underexplored (PMID: 34848247).

Key Findings (Statistical Evidence)

Finding 1: ADHD Worldwide Prevalence

The worldwide-pooled prevalence of ADHD in children <=18 years is 5.29% based on a meta-analysis of 102 studies comprising 171,756 subjects from all world regions (PMID: 17541055). Critically, prevalence does not vary by geographic location or year of study when standardized assessment procedures are used (PMID: 24464188). Adult prevalence is approximately 2.5%.

Finding 2: High Heritability and Polygenic Architecture

ADHD has a mean heritability of 0.74-0.77 from twin studies. The first GWAS meta-analysis identified 12 genome-wide significant loci from 20,183 cases and 35,191 controls (PMID: 30478444). Candidate gene meta-analyses confirmed associations with DAT1, DRD4, DRD5, 5HTT, HTR1B, and SNAP25 (PMID: 19506906). Both common and rare genetic variants contribute independently to ADHD risk.

Finding 3: Fronto-Striatal-Cerebellar Circuit Dysfunction

ADHD involves catecholamine dysregulation in fronto-striatal-cerebellar circuits. Meta-analysis of 55 fMRI studies demonstrates hypoactivation in frontoparietal and ventral attentional networks with hyperactivation in default mode, ventral attention, and somatomotor networks in children with ADHD (PMID: 22983386). The catecholamine hypothesis is supported by the mechanism of action of effective treatments (PMID: 15950012).

Finding 4: Treatment Efficacy

Stimulants and non-stimulants show significant efficacy with moderate-to-large effect sizes. Amphetamines (Hedge's g = 0.51), methylphenidate (g = 0.38), and atomoxetine (g = 0.30) significantly improve quality of life versus placebo (PMID: 38823477). Physical exercise demonstrates the highest effect size (Morris d = 0.93) among non-pharmacological interventions for cognitive difficulties (PMID: 31629998).

Finding 5: International Consensus Validation

An international consensus statement generated 208 empirically supported statements about ADHD, endorsed by 80 authors from 27 countries and 366 additional endorsers (PMID: 33549739). This establishes ADHD as a valid, well-characterized neurodevelopmental disorder with robust evidence across all domains.

Mechanistic Model / Interpretation

The pathophysiology of ADHD can be understood through a multi-level model integrating genetic susceptibility, environmental exposures, epigenetic modifications, and neurodevelopmental consequences:

Level 1 — Genetic Architecture: ADHD is highly polygenic (h-squared approximately 0.74) with 12+ genome-wide significant common variant loci plus rare pathogenic variants in approximately 13% of cases. Key susceptibility genes cluster in dopaminergic (SLC6A3, DRD4, DRD5), serotonergic (SLC6A4, HTR1B), and synaptic (SNAP25, ADGRL3) pathways. Common and rare variants contribute independently, suggesting multiple genetic routes to the disorder.

Level 2 — Gene-Environment Interaction: Environmental exposures (prenatal smoking, alcohol, lead, endocrine disruptors) interact with genetic susceptibility through epigenetic mechanisms including DNA methylation changes at key loci (DRD4 promoter) and genome-wide histone modifications. The amygdala serotonin transporter gene network exemplifies how polygenic risk interacts with postnatal adversity to alter brain structure and behavior.

Level 3 — Neurodevelopmental Impact: Risk genes show peak expression during prenatal brain development, particularly in excitatory glutamatergic neurons. Genetic variants modulate gene expression in the fetal brain, disrupting normal neurodevelopmental processes including neuronal migration, synaptogenesis, and circuit formation.

Level 4 — Catecholamine Dysregulation: The downstream consequence is an imbalance between dopaminergic and noradrenergic systems, particularly in the prefrontal cortex (hypodopaminergic + hypernoradrenergic) and striatum (hypodopaminergic). This produces suboptimal stimulation of postsynaptic receptors in circuits critical for attention, inhibitory control, and motor regulation.

Level 5 — Circuit Dysfunction: Fronto-striatal-cerebellar circuits show both structural (reduced volumes, particularly cerebellar vermis) and functional (hypoactivation in frontoparietal networks, hyperactivation in default mode network) abnormalities. The balance between task-positive and task-negative networks is disrupted.

Level 6 — Clinical Manifestation: Circuit dysfunction produces the core symptom triad: inattention (frontoparietal hypoactivation), hyperactivity (somatomotor network hyperactivation, reduced cerebellar regulation), and impulsivity (impaired response inhibition from inferior frontal dysfunction). Associated features include executive dysfunction, emotional dysregulation, and reward processing abnormalities.

Evidence Base

Landmark Papers

PMID Title/Topic Key Contribution
PMID: 30478444 Discovery of first genome-wide significant ADHD risk loci 12 GWS loci from 20,183 cases
PMID: 33549739 World Federation of ADHD Consensus Statement 208 evidence-based conclusions
PMID: 17541055 Worldwide ADHD prevalence meta-analysis 5.29% pooled prevalence
PMID: 22983386 fMRI meta-analysis (55 studies) Neural systems dysfunction map
PMID: 26386541 Lancet ADHD review Authoritative clinical overview
PMID: 19506906 Candidate gene meta-analysis DAT1, DRD4, DRD5, 5HTT, HTR1B, SNAP25
PMID: 15950012 Neuropsychopharmacology of ADHD Catecholamine hypothesis
PMID: 38823477 Pharmacotherapy QoL meta-analysis Treatment effect sizes
PMID: 34174276 Evidence-based pharmacological treatment Treatment guidelines overview
PMID: 24464188 ADHD prevalence meta-regression update Prevalence stability over 3 decades
PMID: 31629998 Non-pharmacological interventions meta-analysis Exercise d=0.93 for cognitive difficulties
PMID: 17718779 Environmental risk factors review Comprehensive risk factor synthesis
PMID: 28459927 Educational and health outcomes Functional impairment quantification
PMID: 41076565 Common and rare variant contributions Independent genetic pathways
PMID: 40739630 Multi-omics integration for ADHD genes LSM6, RPS26 in fetal brain

Limitations and Knowledge Gaps

  1. Diagnostic heterogeneity: ADHD is likely a collection of related disorders with distinct genetic architectures and pathophysiological mechanisms, rather than a single entity. Current diagnostic categories may obscure biologically meaningful subtypes.

  2. Missing heritability: Despite h-squared of approximately 0.74, identified genetic variants explain only a fraction of this heritability. Additional risk variants, rare variants, structural variants, and epigenetic modifications remain to be discovered.

  3. Lack of validated biomarkers: No biomarker is currently approved for clinical ADHD diagnosis. EEG theta/beta ratio and neuroimaging findings remain research tools.

  4. Long-term treatment outcomes: Most treatment trials are short-term (weeks to months). Long-term efficacy and safety data, particularly for stimulants across the lifespan, are insufficient. Medications are "not efficacious on additional relevant outcomes, such as quality of life, and evidence in the longer term is underinvestigated" (PMID: 39701638).

  5. Sex differences: Females with ADHD are likely underdiagnosed and understudied. Most genetic studies have male-predominant samples.

  6. Gene-environment interaction mechanisms: The precise molecular pathways through which environmental exposures interact with genetic risk remain poorly characterized.

  7. Adult ADHD characterization: DSM symptoms were originally developed for children; adult-specific symptoms (emotional lability, time perception difficulties, racing thoughts) are inadequately captured by current diagnostic tools (PMID: 41640011).

  8. Gut-brain axis role: While emerging evidence implicates gut microbiota in ADHD pathophysiology, causal relationships remain unestablished and specific microbial signatures need replication.

Proposed Follow-up Experiments/Actions

  1. Larger multi-ancestry GWAS: Expand beyond European-ancestry populations to identify population-specific risk loci and improve polygenic risk prediction across diverse populations.

  2. Longitudinal multi-omics studies: Integrate transcriptomics, proteomics, metabolomics, and epigenomics in developmental cohorts from prenatal period through adulthood to map the molecular trajectory of ADHD.

  3. Biomarker validation trials: Conduct prospective studies evaluating combined EEG + serum neurotrophic factor panels (AUC 0.90 for subtype differentiation) as diagnostic aids in clinical settings.

  4. Pharmacogenomic-guided treatment RCTs: Test whether CYP2D6, SLC6A3, SLC6A2, and ADGRL3 genotype-guided prescribing improves treatment response rates versus standard trial-and-error approaches.

  5. Gut microbiome intervention trials: Randomized controlled trials of targeted probiotic/prebiotic interventions in children at high genetic risk for ADHD, measuring both microbiome changes and behavioral outcomes.

  6. Single-cell genomics of ADHD brain tissue: Characterize cell-type-specific gene expression changes in postmortem brain tissue from ADHD cases versus controls, focusing on catecholaminergic neurons and glia.

  7. Sex-stratified analyses: Conduct adequately powered genetic and neuroimaging studies in female-enriched samples to characterize sex-specific ADHD pathophysiology.

  8. Environmental exposure reduction interventions: Test whether population-level reductions in lead, phthalate, and BPA exposure translate to measurable decreases in ADHD incidence.

  9. Adult ADHD symptom scale development: Develop and validate diagnostic instruments that capture the full adult ADHD phenotype including emotional dysregulation, time perception difficulties, and internal restlessness.

  10. Long-term treatment outcomes studies: 5-10 year prospective studies comparing multimodal treatment approaches with medication-only and psychosocial-only strategies, measuring functional outcomes across education, employment, relationships, and health.

Report generated: 2026-05-05 | Based on systematic analysis of 107 published studies | 5 confirmed findings from iterative hypothesis testing